

# BMJ Open

## Short-term use of remifentanyl during endotracheal extubation for prophylactic analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy Study): a study protocol and statistical analysis plan for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005635
Article Type:	Protocol
Date Submitted by the Author:	06-May-2014
Complete List of Authors:	Wu, Yuan-Xing; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine Chen, Han; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine Zhou, Jian-Xin; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Intensive care, Neurology
Keywords:	Adult intensive & critical care < ANAESTHETICS, Anaesthesia in neurology < ANAESTHETICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Short-term use of remifentanil during endotracheal extubation for prophylactic**  
5  
6 **analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy**  
7  
8 **Study): a study protocol and statistical analysis plan for a randomized controlled**  
9  
10 **trial**  
11  
12

13  
14  
15  
16 Yuan-Xing Wu, Han Chen, Jian-Xin Zhou\*

17  
18 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical

19  
20 University, Beijing, 100050, China  
21  
22

23  
24  
25  
26 \*: Corresponding author  
27

28  
29 Jian-Xin Zhou

30  
31 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical

32  
33 University  
34

35  
36 Address: No 6, Tiantan Xili, Dongcheng district, Beijing, 100050, China  
37

38  
39 Telephone: +8610 67098019  
40

41  
42 Email: zhoujx.cn@gmail.com  
43  
44

45  
46 Keywords: remifentanil, analgesia, prophylactic, extubation, craniotomy  
47  
48

49  
50  
51 Word count: 2569  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Acute pain is common during endotracheal extubation period, and is related to complications and adverse outcomes. Patients with delayed extubation after craniotomy are vulnerable to pain and complications of extubation. However, pain control during extubation is still inadequate. Remifentanyl, a new opioid with rapid onset and short duration of action, provides adequate analgesia during procedures with minimal effect of respiratory depression.

**Methods and analysis:** The study is a prospective, randomized, double-blinded, controlled, parallel-group design. Patients with delayed extubation after intracranial surgery are screened daily. Adult patients ready for extubation are enrolled and assigned randomly to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Patients in Remi group receive intravenous bolus dose of remifentanyl 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride at a volume and rate equal to that of remifentanyl. Pain intensity is measured by visual analog scale (VAS) pain score. Adverse events during drug infusion are documented and reported. Patients will be followed up until hospital discharge, death or 60 days after the trial intervention, on first-served basis. Incidence of re-intubation and re-operation within 72 hours after extubation, length of stay in intensive care unit and hospital and mortality are collected. The primary endpoint is the incidence of severe pain (defined as VAS pain score more than 5 cm) during peri-extubation period (defined as the period of time from immediately before extubation to 20 minutes after

1  
2  
3  
4 extubation).

5  
6 **Ethics and dissemination:** The study was approved by the IRB of Beijing Tiantan  
7  
8 Hospital, Capital Medical University. Study findings will be disseminated through  
9  
10 peer-reviewed publications and conference presentations.  
11  
12

13  
14 **Trial Registration:** ClinicalTrials (NCT): ChiCTR-PRC-13003879.  
15  
16

### 17 18 19 **Main strengths and limitations of the study**

20  
21 Pain is common during extubation period, and related to complications and adverse  
22  
23 outcome. Adequate analgesia is needed in this situation. The main strength of the study  
24  
25 is that we will provide the evidence of a new opioid (remifentanyl) with minimal  
26  
27 respiratory depression effect and a rapid onset and short duration of action, for  
28  
29 prophylactic analgesia during extubation in patients after craniotomy.  
30  
31

32  
33 Other opioids may be suitable for prophylactic analgesia during extubation. The main  
34  
35 limitation of the study is that we do not use other opioids, such as morphine or fentanyl,  
36  
37 as control groups.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Clinical epidemiology studies have shown that critically ill patients in intensive care unit (ICU) are at high-risk of pain, and inadequate treatment of pain is associated with adverse outcomes [1,2]. Appropriate analgesia, not only attenuates stress response resulted from pain, but also reduces the incidence of iatrogenic complications, shorten the duration of mechanical ventilation and length of stay (LOS) in ICU [3-5]. In addition to pain at rest, pain related to procedures is common in ICU patients, and inadequate treatment of procedural pain remains a significant problem for many patients [6]. The revised clinical practice guidelines for management of pain, agitation, and delirium from Society of Critical Care Medicine (SCCM) also recommend that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to chest tube removal and other types of potentially painful procedures, and suggest that intravenous opioids should be considered as the first-line drug class of choice [7]. Manipulation of artificial airway, especially endotracheal extubation is among the high pain-intensity procedures in ICU. By using the patient's self-report pain scale as pain evaluation method, Gacouin et al. found that 45% of patients experienced severe pain at the time of endotracheal extubation [8]. Acute pain during extubation is associated with sympathetic nervous system activation, which could result in respiratory and circulatory instability [9]. Therefore, it is reasonable to control pain and stress responses at the time of endotracheal extubation in some high-risk patients, such as those after intracranial surgery. It has been reported that the proportion of patients who underwent delayed extubation after craniotomy is about 10% to 50% [10,11]. These

1  
2  
3  
4 patients are vulnerable to pain and complications of extubation [12]. On the other hand,  
5  
6 despite a greater awareness of pain during endotracheal extubation, clinicians remain  
7  
8 reluctant to administer opioids in patients following craniotomy. The major concern is  
9  
10 the side effects of respiratory depression and influence on consciousness of these drugs.  
11  
12 To our knowledge, up to now, no study has been published for adequate management of  
13  
14 pain during extubation in patients with delayed extubation after craniotomy.  
15  
16

17  
18 Remifentanyl is a potent synthetic selective  $\mu$ -opioid receptor agonist with a rapid onset  
19  
20 and short duration of action, regardless of the duration of its administration [13,14].  
21  
22

23  
24 Remifentanyl differs from other synthetic opioids in its metabolism by non-specific  
25  
26 plasma and tissue esterases. Study in human volunteers has shown that the respiratory  
27  
28 depression of remifentanyl by bolus injection is mild and easily treated with requests to  
29  
30 breathe or the administration of oxygen [15]. These pharmacological properties suggest  
31  
32 that remifentanyl could be a potentially safe and effective analgesic in clinical situations  
33  
34 requiring a brief period of intense control of pain, such as painful procedures in ICU  
35  
36 [16]. There have been reported remifentanyl used as prophylactic analgesia during  
37  
38 removal of chest drain [17], insertion and removal of long-term central venous access  
39  
40 [18], dressing change [19], and endotracheal suctioning [20]. However, although a  
41  
42 plenty of studies have shown that the remifentanyl facilitates emergency in general  
43  
44 anesthesia and weaning process in mechanical ventilation [14,16,21], study for  
45  
46 prophylactic use of remifentanyl in endotracheal extubation is limited.  
47  
48

49  
50 There has been increased interest in use of remifentanyl in brain injured patients. In  
51  
52 patients with traumatic brain injury, it has been demonstrated that remifentanyl has no  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 significant changes in systematic and cerebral hemodynamics, such as intracranial  
5  
6 pressure, mean blood pressure, cerebral perfusion pressure, and cerebral blood flow  
7  
8 velocity [22]. Several studies also compared remifentanyl with fentanyl or morphine as  
9  
10 analgesic in neurologic ICU patients. A randomized multicenter study in patients with  
11  
12 brain injury showed that mean neurologic assessment times were significantly shorter  
13  
14 with remifentanyl than with fentanyl or with morphine, and patients were extubated  
15  
16 significantly faster after remifentanyl than after morphine [23]. Another retrospective  
17  
18 study investigated patients with delayed extubation after brain tumor surgery, and  
19  
20 found that mean extubation times were significantly shorter after remifentanyl/propofol  
21  
22 than after fentanyl/midazolam, and LOS in ICU was significantly reduced [24]. These  
23  
24 results indicate that the rapid metabolism and lack of accumulation of remifentanyl  
25  
26 facilitate faster waking and neurological assessment, and suggest that remifentanyl  
27  
28 might be a better choice of analgesic in patients with brain injury.  
29  
30  
31  
32  
33  
34

35  
36 In present study, remifentanyl is used as prophylactic analgesics in patients with delayed  
37  
38 extubation after craniotomy. The aim is to evaluate the efficacy and safety of  
39  
40 remifentanyl for control of pain and stress responses due to extubation. The primary  
41  
42 hypothesis is that prophylactic use of remifentanyl will reduce the incidence of severe  
43  
44 pain during endotracheal extubation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

### Study design overview

The present study is a prospective, single-center, randomized, double-blinded, placebo-controlled, two-arm trial in patients with delayed extubation after craniotomy.

Trial schematic diagram is shown in Figure 1.

### Study setting and population

The study setting is neurosurgical ICU (30 beds), Beijing Tiantan Hospital (1100 beds), Capital Medical University, Beijing, China.

All patients after intracranial surgery with delayed extubation admitted to our ICU are screened daily for study eligibility.

Inclusion criteria are:

- 1) Age between 18-65 years-old;
- 2) Within 72 hours after operation;
- 3) Awaken and able to cope with the assessment of visual analog scale (VAS) pain score;
- 4) Ready for extubation after evaluated by neurosurgeon and ICU physician in charge.

Exclusion criteria are:

- 1) Operation relating to medulla oblongata region;
- 2) Hepatic Insufficiency;



- 3) Renal insufficiency;
- 4) Pregnant or lactating women;
- 5) Need continuous infusion of vasopressor before the start of study drug infusion;
- 6) Chronic opioid use over three months;
- 7) Known opioids allergy;
- 8) Readmitted to ICU after randomization to the study;
- 9) Enrolled in another trial.

Patient's endotracheal tube is extubated at the discretion of neurosurgeon and ICU physician in charge of the patient. Neurosurgeon and ICU physician discuss the patient's status and evaluate the patient by a screen checklist (Table 1) [10]. When answers of all items in checklist are "yes", the patient is ready for extubation. At this time, a 24-hour on-call study coordinator will be informed immediately, and patient's eligibility for the study is evaluated and confirmed.

#### **Randomization, double-blind and allocation concealment**

The study has a prospective, randomized, double-blinded, controlled, parallel-group design. Consecutive patients are randomly assigned to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Randomization is based on computer generated random digits table and follows a concealed process using sealed and numbered envelopes that allocate the patient to either of the two arms of the study. Patients may be randomized into this study only once unless they were discharged from the hospital and were re-admitted beyond 180 days of the first enrollment. The study

1  
2  
3  
4 does not allow cross-over and, if any occur, they will be reported as protocol violations.  
5  
6 Experimental drug and placebo with the same character are prepared by a pharmacist.  
7  
8 Patients and all study personnel except the investigative pharmacist are blind to  
9  
10 treatment assignment. The details of the series are unknown to any of the investigators  
11  
12 and are contained in a set of opaque and sealed envelopes, each bearing on the outside  
13  
14 only the number.  
15  
16  
17  
18  
19  
20

### 21 **Data collected at study entry**

22  
23 At baseline, data on demographic, history of past illness characteristics and diagnosis  
24  
25 of the patients are obtained. The surgical site, operation time, use of sedatives and  
26  
27 analgesics during anesthesia and ICU stay, time of mechanical ventilation, formulation  
28  
29 and dose of postoperative patient-control-analgesia (PCA) pump, and time between end  
30  
31 of operation and study drug infusion are recorded. Acute Physiology and Chronic  
32  
33 Health Evaluation II score (APACHE II) is calculated.  
34  
35  
36  
37  
38  
39  
40

### 41 **Trial interventions**

42  
43 All patients are randomized 1:1 to receive remifentanyl (Remi group) or placebo (Saline  
44  
45 group) infusion. Patients in Remi group receive intravenous bolus dose of remifentanyl  
46  
47 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20  
48  
49 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride  
50  
51 at a volume and rate equal to that of remifentanyl. Study drugs are administered by  
52  
53 using syringe pump.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Immediately after drug infusion, ICU physician evaluate the patient by using  
5  
6 extubation screen checklist shown in Table 1. If the patient passes the evaluation,  
7  
8 endotracheal extubation will be carried out immediately by registered ICU nurses. The  
9  
10 patient will be labeled as “failing to pass extubation test after drug administration” if he  
11  
12 or she does not pass the evaluation. The reason of test failure will be documented. The  
13  
14 patient will be re-evaluated every hour thereafter, and data about extubation will be  
15  
16 documented.  
17  
18  
19

20  
21 Vital signs, which including heart rate (HR), respiratory rate (RR), non-invasive blood  
22  
23 pressure (BP) and pulse oxygen saturation (SpO<sub>2</sub>), are continuously monitored. VAS  
24  
25 pain score is used to measure the pain intensity by the study investigator [25]. Each  
26  
27 patient is instructed and asked to point to a mark on a 10-cm horizontal line labelled  
28  
29 with descriptors of pain intensity (‘No pain’ at the 0 cm point and ‘Extreme pain’ at the  
30  
31 10 cm point). VAS and vital signs (HR, RR, BP and SpO<sub>2</sub>) are documented at four time  
32  
33 points: before drug infusion (baseline), immediately before extubation, immediately to  
34  
35 3 minutes after extubation and 20 minutes after extubation.  
36  
37  
38  
39

40  
41 Patients will be followed up until hospital discharge, death or 60 days after the trial  
42  
43 intervention, on first-served basis. Following data are collected: incidence of  
44  
45 re-intubation within 72 hours after extubation, incidence of re-operation due to  
46  
47 intracranial hemorrhage or edema within 72 hours after extubation, LOS in ICU and  
48  
49 hospital and mortality.  
50  
51  
52

### 53 54 55 56 **Adverse events management and emergency stop of the study drug** 57 58 59 60

1  
2  
3  
4 Patients are closely monitored during study drug infusion. Taking into account the  
5  
6 potential adverse effects of remifentanyl, experimental drugs must be immediately  
7  
8 terminated when the following occurs:  
9

- 10  
11 1) Unresponsive to calling and patting on the shoulder;
- 12  
13 2) RR less than 8 respirations per minute and SpO<sub>2</sub> less than 92%;
- 14  
15 3) HR less than 50 beats per minute after atropine in 0.25 mg bolus;
- 16  
17 4) Systolic BP less than 90 mmHg;
- 18  
19 5) Serious allergic reaction such as throat swelling, bronchospasm or skin rash.  
20  
21  
22

23  
24 These data will be documented and reported as adverse events.  
25  
26  
27

### 28 29 **Study endpoints**

30  
31 The primary endpoint of present study is the incidence of severe pain during  
32  
33 peri-extubation period. Peri-extubation is defined as the period of time from  
34  
35 immediately before extubation to 20 minutes after extubation. Severe pain is defined as  
36  
37 one of the VAS pain scores is more than 5 cm.  
38  
39

40  
41 Secondary endpoints include:  
42

- 43  
44 1) VAS pain score and vital signs (HR, RR, BP and SpO<sub>2</sub>) during peri-extubation  
45  
46 period;
- 47  
48 2) Incidence of failing to pass extubation evaluation after experimental drug  
49  
50 infusion;
- 51  
52 3) Incidence of re-intubation within 72 hours after extubation;
- 53  
54  
55 4) Incidence of re-operation due to intracranial hemorrhage or edema within 72  
56  
57  
58  
59  
60

hours after extubation;

- 5) Incidence of adverse events during experimental drug infusion;
- 6) LOS in ICU and hospital;
- 7) Mortality.

### **Current sample size justification**

Primarily, we expect the incidence of severe pain during peri-extubation period to decrease after remifentanyl infusion in delayed extubation patients after craniotomy.

Previous investigation showed that severe peri-extubation pain was occurred in 45% of patients [8]. It is expected that the incidence of severe pain would decrease to 30% after remifentanyl infusion. Using the Power and Sample Size Calculation program, we will need to study 74 experimental subjects and 74 control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with a probability (power) of 0.8. The Type I error probability with testing this null hypothesis is 0.05.

### **Statistical analysis**

All analyses will be according to the intention-to-treat principle, that is, all randomized patients will be analyzed in the groups to which they were originally allocated and will be blinded to treatment assignment.

Baseline characteristics will be summarized by univariate analyses. Categorical variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test.

1  
2  
3  
4 Continuous variables will be checked for normal distribution and presented as mean  
5  
6 and standard deviation or median and interquartile range as appropriate. Comparison of  
7  
8 continuous variables will be performed by using Student's t-test for normally  
9  
10 distributed variables and the Mann-Whitney U test for non-normally distributed  
11  
12 variables.  
13  
14

15  
16 We use repeated measure of analysis of variance (ANOVA) for comparing VAS pain  
17  
18 score and vital signs (HR, RR, BP and SpO<sub>2</sub>) across different time points (before drug  
19  
20 infusion and during peri-extubation period) between the two groups.  
21  
22

23  
24 All tests of significance will be at the 5% significance level, and two-sided. Analyses  
25  
26 are conducted by using SPSS 17.0.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ETHICS AND DISSEMINATION

### **Ethical aspects and informed consent**

Patients with delayed extubation after craniotomy are often unable to provide consent before extubation. After patient's eligibility for the study is confirmed, the ICU physician will introduce the family to the study coordinator. The physician will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program that is being conducted, and that this person is qualified to do so. The study coordinator will take the family to a place where they can talk confidentially. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand.

The study coordinator will explain that the patient may experience pain during extubation and, if so, the patient could become worse. The coordinator will say that a new opioid drug, remifentanyl provides adequate analgesia with minimal respiratory depression. He (or she) will explain that in a small percentage of patients, remifentanyl could cause bradycardia, hypotension and respiratory depression. The potential advantages of using or not using remifentanyl will be described. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study

1  
2  
3 coordinator, local co-investigator and the local Ethical Committee. Written consent will  
4  
5  
6 be obtained in the presence of a witness.  
7

8  
9 A register is kept of all patients evaluated for inclusion and of patients who withdraw  
10  
11 from the study. The latter are clinically followed up without their data being analyzed in  
12  
13 the study.  
14

15  
16 The study protocol and consent forms were approved on November 1, 2013 by the  
17  
18 Institutional Review Board of Beijing Tiantan Hospital Affiliated to Capital Medical  
19  
20 University (approval number KY2013-002-01). The study was registered on November  
21  
22 8, 2013 at the Chinese Clinical Trial Registry (ChiCTR-PRC-13003879).  
23  
24  
25

### 26 27 28 **Dissemination plan** 29

30  
31 Results of the trial will be submitted to international peer reviewed journal. Results will  
32  
33 also be presented at national and international conferences relevant to subject fields.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**TRIAL STATUS**

The first patient was enrolled on January 06, 2014. The study will be completed in December 2014.

For peer review only

**SUMMARY**

Endotracheal extubation is a critical step during post-operative care in neurosurgical patients [9]. Pain is common during extubation period, and related to complications and adverse outcome [8]. Adequate analgesia is needed in this situation. Although revised Clinical Practice Guidelines from SCCM have recommended that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to potentially painful procedures [7], study for analgesia during endotracheal extubation is still limited. As a new opioid with minimal respiratory depression effect and a rapid onset and short duration of action, remifentanyl seems suitable for prophylactic analgesia during extubation in patients after craniotomy [13-16]. We want to provide such evidence in present study. Even a neutral result will provide important insight, as this would mean that more studies are needed to explore a safe and effective way of pain management during endotracheal extubation.

## REFERENCES

1. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. *Anesthesiology* 2007;**106**:687-95.
2. Chanques G, Sebbane M, Barbotte E, et al. A prospective study of pain at rest: Incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. *Anesthesiology* 2007;**107**:858-60.
3. Robinson BR, Mueller EW, Henson K, et al. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. *J Trauma* 2008;**65**:517-26.
4. Payen JF, Bosson JL, Chanques G, et al. DOLOREA Investigators. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: A post Hoc analysis of the DOLOREA study. *Anesthesiology* 2009;**111**:1308-16.
5. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. *Crit Care Med* 2006;**34**:1691-9.
6. Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. *Am J Crit Care* 2001;**10**:238-51.
7. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine:

- 1  
2  
3  
4 Clinical practice guidelines for the management of pain, agitation, and delirium  
5  
6 in adult patients in the intensive care unit. *Crit Care Med* 2013;**41**:263-306.  
7  
8  
9 8. Gacouin A, Camus C, Le Tulzo Y, et al. Assessment of peri-extubation pain by  
10  
11 visual analogue scale in the adult intensive care unit: a prospective  
12  
13 observational study. *Intensive Care Med* 2004;**30**:1340-7.  
14  
15  
16 9. Difficult Airway Society Extubation Guidelines Group, Popat M, Mitchell V, et  
17  
18 al. Difficult Airway Society Guidelines for the management of tracheal  
19  
20 extubation. *Anaesthesia* 2012;**67**:318-40.  
21  
22  
23  
24 10. Cai YH, Zeng HY, Shi ZH, et al. Factors influencing delayed extubation after  
25  
26 infratentorial craniotomy for tumour resection: a prospective cohort study of  
27  
28 800 patients in a Chinese neurosurgical centre. *J Int Med Res* 2013;**41**:208-17.  
29  
30  
31  
32 11. Cata JP, Saager L, Kurz A, et al. Successful extubation in the operating room  
33  
34 after infratentorial craniotomy: the Cleveland Clinic experience. *J Neurosurg*  
35  
36 *Anesthesiol* 2011;**23**:25-9.  
37  
38  
39 12. Bruder N, Ravussin P. Recovery from anesthesia and postoperative extubation  
40  
41 of neurosurgical patients: a review. *J Neurosurg Anesthesiol* 1999;**11**:282-93.  
42  
43  
44 13. Glass PS, Gan TJ, Howell S. A review of the pharmacokinetics and  
45  
46 pharmacodynamics of remifentanil. *Anesth Analg* 1999;**89**(4 Suppl):S7-S14.  
47  
48  
49 14. Beers R, Camporesi E. Remifentanil update: clinical science and utility. *CNS*  
50  
51 *drugs* 2004;**18**:1085-104.  
52  
53  
54 15. Egan TD, Kern SE, Muir KT, et al. Remifentanil by bolus injection: a safety,  
55  
56 pharmacokinetic, pharmacodynamic, and age effect investigation in human  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- volunteers. *Br J Anaesth* 2004;**92**:335-43.
16. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanyl. *Crit Care* 2008;**12**(Suppl 3):S5.
17. Casey E, Lane A, Kuriakose D, et al. Bolus remifentanyl for chest drain removal in ICU: a randomized double-blind comparison of three modes of analgesia in post-cardiac surgical patients. *Intensive Care Med* 2010;**36**:1380-5.
18. Burlacu CL, McKeating K, McShane AJ. Remifentanyl for the insertion and removal of long-term central venous access during monitored anesthesia care. *J Clin Anesth* 2011;**23**:286-91.
19. Le Floch R, Naux E, Pilorget A, et al. Use of remifentanyl for analgesia during dressing change in spontaneously breathing non-intubated burn patients. *Ann Burns Fire Disasters* 2006;**19**:136-9.
20. Leone M, Albanese J, Viviani X, et al. The effects of remifentanyl on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients. *Anesth Analg* 2004;**99**:1193-8.
21. Kim SY, Yang SY, Na SW, et al. Low-dose remifentanyl infusion during ventilator weaning and tracheal extubation in postoperative intensive care unit patients sedated with propofol-remifentanyl: a randomised clinical trial. *Anaesth Intensive Care* 2012;**40**:656-62.
22. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanyl on intracranial pressure and cerebral blood flow velocity in patients with head trauma. *Acta Anaesthesiol Scand* 2004;**48**:396-9.

- 1  
2  
3  
4 23. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of  
5  
6 analgesia- based sedation using remifentanil versus standard hypnotic-based  
7  
8 regimens in intensive care unit patients with brain injuries: a randomised,  
9  
10 controlled trial [ISRCTN50308308]. Crit Care 2004;**8**:R268-R280.  
11  
12  
13  
14 24. Bauer C, Kreuer S, Ketter R, et al. Remifentanil-propofol versus  
15  
16 fentanyl-midazolam combina- tions for intracranial surgery: Influence of  
17  
18 anaesthesia tech- nique and intensive sedation on ventilation times and duration  
19  
20 of stay in the ICU. Anaesthetist 2007;**56**:128-32.  
21  
22  
23  
24  
25 25. Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg  
26  
27 Med 1996;**27**:427-32.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions**

YXW and JXZ participated in the design of the study and drafted the manuscript. HC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement**

The study was funded by Beijing Health Bureau (No: 2009-3-28). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

**Competing interests**

The authors declare that they have no competing interests.

**Table 1: Screening checklist used to determine the patient's suitability for extubation**

Question	Answer
1. Awake and alert with cerebral function adequate for patient co-operation or equivalent preoperative state of consciousness?	Yes/No
2. Hemodynamic stability (lack of vasopressor support and mean arterial pressure within 10-15% of baseline)?	Yes/No
3. Adequate recovery of muscle strength?	Yes/No
4. Normal tidal volumes, normocapnia (end-tidal carbon dioxide 30-45 mmHg), minimum pulse oximetry > 95% with FiO <sub>2</sub> 0.5?	Yes/No
5. Intact gag reflex and swallow function (presence of clearly audible cough during suctioning)?	Yes/No

The answer to all questions must be "yes" in order for extubation to be approved.

FiO<sub>2</sub>: fraction of inspired oxygen




1  
2  
3  
4 **Figure legend**  
5  
6

7 Figure 1: Trial schematic diagram  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



309x249mm (150 x 150 DPI)

View Only



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4-6
	2b	Specific objectives or hypotheses	6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7, 9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Not applicable
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	9-11
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	11-12
	6b	Any changes to trial outcomes after the trial commenced, with reasons	Not applicable
Sample size	7a	How sample size was determined	12
	7b	When applicable, explanation of any interim analyses and stopping guidelines	Not applicable
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	8-9
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8-9
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8-9
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8-9
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	8-9
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	12-13
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	Not applicable
7			
8	<b>Results</b>		
9	Participant flow (a diagram is strongly recommended)	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Not applicable in items 13a to 22
10			
11			
12		13b For each group, losses and exclusions after randomisation, together with reasons	
13	Recruitment	14a Dates defining the periods of recruitment and follow-up	
14		14b Why the trial ended or was stopped	
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
17			
18	Outcomes and estimation	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
19		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
20	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
21			
22	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
23			
24	<b>Discussion</b>		
25	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
26	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	
27	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
28			
29	<b>Other information</b>		
30	Registration	23 Registration number and name of trial registry	ChiCTR-PRC-13003879
31			
32	Protocol	24 Where the full trial protocol can be accessed, if available	Not applicable
33	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	The study was supported by Beijing Health
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44	CONSORT 2010 checklist		Page 2
45			
46			
47			
48			
49			

---

Bureau (No: 2009-3-28).  
The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

---

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

# BMJ Open

## Short-term use of remifentanyl during endotracheal extubation for prophylactic analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy Study): a study protocol and statistical analysis plan for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005635.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Aug-2014
Complete List of Authors:	Wu, Yuan-Xing; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine Chen, Han; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine Zhou, Jian-Xin; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Intensive care, Neurology
Keywords:	Adult intensive & critical care < ANAESTHETICS, Anaesthesia in neurology < ANAESTHETICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Short-term use of remifentanil during endotracheal extubation for prophylactic**  
5  
6 **analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy**  
7  
8 **Study): a study protocol and statistical analysis plan for a randomized controlled**  
9  
10 **trial**  
11  
12

13  
14  
15  
16 Yuan-Xing Wu, Han Chen, Jian-Xin Zhou\*

17  
18 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical

19  
20 University, Beijing, 100050, China  
21  
22

23  
24  
25  
26 \*: Corresponding author  
27

28  
29 Jian-Xin Zhou

30  
31 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical

32  
33 University  
34

35  
36 Address: No 6, Tiantan Xili, Dongcheng district, Beijing, 100050, China  
37

38  
39 Telephone: +8610 67098019  
40

41  
42 Email: zhoujx.cn@gmail.com  
43  
44

45  
46 Keywords: remifentanil, analgesia, prophylactic, extubation, craniotomy  
47  
48

49  
50  
51 Word count: 2569  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Acute pain is common during endotracheal extubation period, and is related to complications and adverse outcomes. Patients with delayed extubation after craniotomy are vulnerable to pain and complications of extubation. However, pain control during extubation is still inadequate. Remifentanyl, a new opioid with rapid onset and short duration of action, provides adequate analgesia during procedures with minimal effect of respiratory depression.

**Methods and analysis:** The study is a prospective, randomized, double-blinded, controlled, parallel-group design. Patients with delayed extubation after intracranial surgery are screened daily. Adult patients ready for extubation are enrolled and assigned randomly to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Patients in Remi group receive intravenous bolus dose of remifentanyl 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride at a volume and rate equal to that of remifentanyl. Pain intensity is measured by visual analog scale (VAS) pain score. Adverse events during drug infusion are documented and reported. Patients will be followed up until hospital discharge, death or 60 days after the trial intervention, on first-served basis. Incidence of re-intubation and re-operation within 72 hours after extubation, length of stay in intensive care unit and hospital and mortality are collected. The primary endpoint is the incidence of severe pain (defined as VAS pain score more than 5 cm) during peri-extubation period (defined as the period of time from immediately before extubation to 20 minutes after



1  
2  
3  
4 extubation).

5  
6 **Ethics and dissemination:** The study was approved by the IRB of Beijing Tiantan  
7  
8 Hospital, Capital Medical University. Study findings will be disseminated through  
9  
10 peer-reviewed publications and conference presentations.  
11  
12

13  
14 **Trial Registration:** ClinicalTrials (NCT): ChiCTR-PRC-13003879.  
15  
16

### 17 18 19 **Main strengths and limitations of the study**

20  
21 Pain is common during extubation period, and related to complications and adverse  
22  
23 outcome. Adequate analgesia is needed in this situation. The main strength of the study  
24  
25 is that we will provide the evidence of a new opioid (remifentanyl) with minimal  
26  
27 respiratory depression effect and a rapid onset and short duration of action, for  
28  
29 prophylactic analgesia during extubation in patients after craniotomy.  
30  
31

32  
33 Other opioids may be suitable for prophylactic analgesia during extubation. The main  
34  
35 limitation of the study is that we do not use other opioids, such as morphine or fentanyl,  
36  
37 as control groups. Because there is no proven dose of remifentanyl which can prevent  
38  
39 sedation and respiratory depression in a neurosurgical patient being weaned off  
40  
41 ventilator, the dose of remifentanyl used in present study is arbitrary.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Clinical epidemiology studies have shown that critically ill patients in intensive care unit (ICU) are at high-risk of pain, and inadequate treatment of pain is associated with adverse outcomes [1,2]. Appropriate analgesia, not only attenuates stress response resulted from pain, but also reduces the incidence of iatrogenic complications, shorten the duration of mechanical ventilation and length of stay (LOS) in ICU [3-5]. In addition to pain at rest, pain related to procedures is common in ICU patients, and inadequate treatment of procedural pain remains a significant problem for many patients [6]. The revised clinical practice guidelines for management of pain, agitation, and delirium from Society of Critical Care Medicine (SCCM) also recommend that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to chest tube removal and other types of potentially painful procedures, and suggest that intravenous opioids should be considered as the first-line drug class of choice [7]. Manipulation of artificial airway, especially endotracheal extubation is among the high pain-intensity procedures in ICU. By using the patient's self-report pain scale as pain evaluation method, Gacouin et al. found that 45% of patients experienced severe pain at the time of endotracheal extubation [8]. Acute pain during extubation is associated with sympathetic nervous system activation, which could result in respiratory and circulatory instability [9]. Therefore, it is reasonable to control pain and stress responses at the time of endotracheal extubation in some high-risk patients, such as those after intracranial surgery. It has been reported that the proportion of patients who underwent delayed extubation after craniotomy is about 10% to 50% [10,11]. These

1  
2  
3  
4 patients are vulnerable to pain and complications of extubation [12]. On the other hand,  
5  
6 despite a greater awareness of pain during endotracheal extubation, clinicians remain  
7  
8 reluctant to administer opioids in patients following craniotomy. The major concern is  
9  
10 the side effects of respiratory depression and influence on consciousness of these drugs.  
11  
12 To our knowledge, up to now, no study has been published for adequate management of  
13  
14 pain during extubation in patients with delayed extubation after craniotomy.  
15  
16

17  
18 Remifentanyl is a potent synthetic selective  $\mu$ -opioid receptor agonist with a rapid onset  
19  
20 and short duration of action, regardless of the duration of its administration [13,14].  
21  
22

23  
24 Remifentanyl differs from other synthetic opioids in its metabolism by non-specific  
25  
26 plasma and tissue esterases. Study in human volunteers has shown that the respiratory  
27  
28 depression of remifentanyl by bolus injection is mild and easily treated with requests to  
29  
30 breathe or the administration of oxygen [15]. These pharmacological properties suggest  
31  
32 that remifentanyl could be a potentially safe and effective analgesic in clinical situations  
33  
34 requiring a brief period of intense control of pain, such as painful procedures in ICU  
35  
36 [16]. There have been reported remifentanyl used as prophylactic analgesia during  
37  
38 removal of chest drain [17], insertion and removal of long-term central venous access  
39  
40 [18], dressing change [19], and endotracheal suctioning [20]. However, although a  
41  
42 plenty of studies have shown that the remifentanyl facilitates emergency in general  
43  
44 anesthesia and weaning process in mechanical ventilation [14,16,21], study for  
45  
46 prophylactic use of remifentanyl in endotracheal extubation is limited.  
47  
48

49  
50 There has been increased interest in use of remifentanyl in brain injured patients. In  
51  
52 patients with traumatic brain injury, it has been demonstrated that remifentanyl has no  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 significant changes in systematic and cerebral hemodynamics, such as intracranial  
5  
6 pressure, mean blood pressure, cerebral perfusion pressure, and cerebral blood flow  
7  
8 velocity [22]. Several studies also compared remifentanyl with fentanyl or morphine as  
9  
10 analgesic in neurologic ICU patients. A randomized multicenter study in patients with  
11  
12 brain injury showed that mean neurologic assessment times were significantly shorter  
13  
14 with remifentanyl than with fentanyl or with morphine, and patients were extubated  
15  
16 significantly faster after remifentanyl than after morphine [23]. Another retrospective  
17  
18 study investigated patients with delayed extubation after brain tumor surgery, and  
19  
20 found that mean extubation times were significantly shorter after remifentanyl/propofol  
21  
22 than after fentanyl/midazolam, and LOS in ICU was significantly reduced [24]. These  
23  
24 results indicate that the rapid metabolism and lack of accumulation of remifentanyl  
25  
26 facilitate faster waking and neurological assessment, and suggest that remifentanyl  
27  
28 might be a better choice of analgesic in patients with brain injury.  
29  
30  
31  
32  
33  
34

35  
36 In present study, remifentanyl is used as prophylactic analgesics in patients with delayed  
37  
38 extubation after craniotomy. The aim is to evaluate the efficacy and safety of  
39  
40 remifentanyl for control of pain and stress responses due to extubation. The primary  
41  
42 hypothesis is that prophylactic use of remifentanyl will reduce the incidence of severe  
43  
44 pain during endotracheal extubation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

### Study design overview

The present study is a prospective, single-center, randomized, double-blinded, placebo-controlled, two-arm trial in patients with delayed extubation after craniotomy.

Trial schematic diagram is shown in Figure 1.

### Study setting and population

The study setting is neurosurgical ICU (30 beds), Beijing Tiantan Hospital (1100 beds), Capital Medical University, Beijing, China.

All patients after intracranial surgery with delayed extubation admitted to our ICU are screened daily for study eligibility.

Inclusion criteria are:

- 1) Age between 18-65 years-old;
- 2) Within 72 hours after operation;
- 3) Awaken and able to cope with the assessment of visual analog scale (VAS) pain score;
- 4) Ready for extubation after evaluated by neurosurgeon and ICU physician in charge.

Exclusion criteria are:

- 1) Operation relating to medulla oblongata region;
- 2) Hepatic Insufficiency;

- 3) Renal insufficiency;
- 4) Pregnant or lactating women;
- 5) Need continuous infusion of vasopressor before the start of study drug infusion;
- 6) Chronic opioid use over three months;
- 7) Known opioids allergy;
- 8) Readmitted to ICU after randomization to the study;
- 9) Enrolled in another trial.

Patient's endotracheal tube is extubated at the discretion of neurosurgeon and ICU physician in charge of the patient. Neurosurgeon and ICU physician discuss the patient's status and evaluate the patient by a screen checklist (Table 1) [10]. When answers of all items in checklist are "yes", the patient is ready for extubation. At this time, a 24-hour on-call study coordinator will be informed immediately, and patient's eligibility for the study is evaluated and confirmed.

#### **Randomization, double-blind and allocation concealment**

The study has a prospective, randomized, double-blinded, controlled, parallel-group design. Consecutive patients are randomly assigned to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Randomization is based on computer generated random digits table and follows a concealed process using sealed and numbered envelopes that allocate the patient to either of the two arms of the study. Patients may be randomized into this study only once unless they were discharged from the hospital and were re-admitted beyond 180 days of the first enrollment. The study

1  
2  
3  
4 does not allow cross-over and, if any occur, they will be reported as protocol violations.  
5  
6 Experimental drug and placebo with the same character are prepared by a pharmacist.  
7  
8 Patients and all study personnel except the investigative pharmacist are blind to  
9  
10 treatment assignment. The details of the series are unknown to any of the investigators  
11  
12 and are contained in a set of opaque and sealed envelopes, each bearing on the outside  
13  
14 only the number.  
15  
16  
17  
18  
19  
20

### 21 **Data collected at study entry**

22  
23 At baseline, data on demographic, history of past illness characteristics and diagnosis  
24  
25 of the patients are obtained. The surgical site, operation time, use of sedatives and  
26  
27 analgesics during anaesthesia and ICU stay, time of mechanical ventilation,  
28  
29 formulation and dose of postoperative patient-control-analgesia (PCA) pump, and time  
30  
31 between end of operation and study drug infusion are recorded. Acute Physiology and  
32  
33 Chronic Health Evaluation II score (APACHE II) is calculated.  
34  
35  
36  
37  
38  
39  
40

### 41 **Trial interventions**

42  
43 All patients are randomized 1:1 to receive remifentanyl (Remi group) or placebo (Saline  
44  
45 group) infusion. Patients in Remi group receive intravenous bolus dose of remifentanyl  
46  
47 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20  
48  
49 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride  
50  
51 at a volume and rate equal to that of remifentanyl. Study drugs are administered by  
52  
53 using syringe pump.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Immediately after drug infusion, ICU physician evaluate the patient by using  
5  
6 extubation screen checklist shown in Table 1. If the patient passes the evaluation,  
7  
8 endotracheal extubation will be carried out immediately by registered ICU nurses. The  
9  
10 patient will be labeled as “failing to pass extubation test after drug administration” if he  
11  
12 or she does not pass the evaluation. The reason of test failure will be documented. The  
13  
14 patient will be re-evaluated every hour thereafter, and data about extubation will be  
15  
16 documented.  
17  
18  
19

20  
21 Vital signs, which including heart rate (HR), respiratory rate (RR), non-invasive blood  
22  
23 pressure (BP) and pulse oxygen saturation (SpO<sub>2</sub>), are continuously monitored. VAS  
24  
25 pain score is used to measure the pain intensity by the study investigator [25]. Each  
26  
27 patient is instructed and asked to point to a mark on a 10-cm horizontal line labelled  
28  
29 with descriptors of pain intensity (‘No pain’ at the 0 cm point and ‘Extreme pain’ at the  
30  
31 10 cm point). VAS and vital signs (HR, RR, BP and SpO<sub>2</sub>) are documented at four time  
32  
33 points: before drug infusion (baseline), immediately before extubation, immediately to  
34  
35 3 minutes after extubation and 20 minutes after extubation.  
36  
37  
38  
39

40  
41 Patients will be followed up until hospital discharge, death or 60 days after the trial  
42  
43 intervention, on first-served basis. Following data are collected: incidence of  
44  
45 re-intubation within 72 hours after extubation, incidence of re-operation due to  
46  
47 intracranial hemorrhage or edema within 72 hours after extubation, LOS in ICU and  
48  
49 hospital and mortality.  
50  
51  
52

### 53 54 55 56 **Adverse events management and emergency stop of the study drug** 57 58 59 60



1  
2  
3  
4 Patients are closely monitored during study drug infusion. Taking into account the  
5  
6 potential adverse effects of remifentanyl, experimental drugs must be immediately  
7  
8 terminated when the following occurs:  
9

- 10  
11 1) Unresponsive to calling and patting on the shoulder;
- 12  
13 2) RR less than 8 respirations per minute and SpO<sub>2</sub> less than 92%;
- 14  
15 3) HR less than 50 beats per minute after atropine in 0.25 mg bolus;
- 16  
17 4) Systolic BP less than 90 mmHg;
- 18  
19 5) Serious allergic reaction such as throat swelling, bronchospasm or skin rash.  
20  
21  
22

23  
24 These data will be documented and reported as adverse events.  
25  
26  
27

### 28 29 **Study endpoints**

30  
31 The primary endpoint of present study is the incidence of severe pain during  
32  
33 peri-extubation period. Peri-extubation is defined as the period of time from  
34  
35 immediately before extubation to 20 minutes after extubation. Severe pain is defined as  
36  
37 one of the VAS pain scores is more than 5 cm.  
38  
39

40  
41 Secondary endpoints include:  
42

- 43  
44 1) VAS pain score and vital signs (HR, RR, BP and SpO<sub>2</sub>) during peri-extubation  
45  
46 period;
- 47  
48 2) Incidence of failing to pass extubation evaluation after experimental drug  
49  
50 infusion;
- 51  
52 3) Incidence of re-intubation within 72 hours after extubation;
- 53  
54  
55 4) Incidence of re-operation due to intracranial hemorrhage or edema within 72  
56  
57  
58  
59  
60

hours after extubation;

- 5) Incidence of adverse events during experimental drug infusion;
- 6) LOS in ICU and hospital;
- 7) Mortality.

### **Current sample size justification**

Primarily, we expect the incidence of severe pain during peri-extubation period to decrease after remifentanyl infusion in delayed extubation patients after craniotomy.

Previous investigation showed that severe peri-extubation pain was occurred in 45% of patients [8]. It is expected that the incidence of severe pain would decrease to 30% after remifentanyl infusion. Using the Power and Sample Size Calculation program, we will need to study 74 experimental subjects and 74 control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with a probability (power) of 0.8. The Type I error probability with testing this null hypothesis is 0.05.

### **Statistical analysis**

All analyses will be according to the intention-to-treat principle, that is, all randomized patients will be analyzed in the groups to which they were originally allocated and will be blinded to treatment assignment.

Baseline characteristics will be summarized by univariate analyses. Categorical variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test.

1  
2  
3  
4 Continuous variables will be checked for normal distribution and presented as mean  
5  
6 and standard deviation or median and interquartile range as appropriate. Comparison of  
7  
8 continuous variables will be performed by using Student's t-test for normally  
9  
10 distributed variables and the Mann-Whitney U test for non-normally distributed  
11  
12 variables.  
13  
14

15  
16 We use repeated measure of analysis of variance (ANOVA) for comparing VAS pain  
17  
18 score and vital signs (HR, RR, BP and SpO<sub>2</sub>) across different time points (before drug  
19  
20 infusion and during peri-extubation period) between the two groups.  
21  
22

23  
24 All tests of significance will be at the 5% significance level, and two-sided. Analyses  
25  
26 are conducted by using SPSS 17.0.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ETHICS AND DISSEMINATION

### Ethical aspects and informed consent

Patients with delayed extubation after craniotomy are often unable to provide consent before extubation. After patient's eligibility for the study is confirmed, the ICU physician will introduce the family to the study coordinator. The physician will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program that is being conducted, and that this person is qualified to do so. The study coordinator will take the family to a place where they can talk confidentially. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand.

The study coordinator will explain that the patient may experience pain during extubation and, if so, the patient could become worse. The coordinator will say that a new opioid drug, remifentanyl provides adequate analgesia with minimal respiratory depression. He (or she) will explain that in a small percentage of patients, remifentanyl could cause bradycardia, hypotension and respiratory depression. The potential advantages of using or not using remifentanyl will be described. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study

1  
2  
3 coordinator, local co-investigator and the local Ethical Committee. Written consent will  
4  
5  
6 be obtained in the presence of a witness.  
7

8  
9 A register is kept of all patients evaluated for inclusion and of patients who withdraw  
10  
11 from the study. The latter are clinically followed up without their data being analyzed in  
12  
13 the study.  
14

15  
16 The study protocol and consent forms were approved on November 1, 2013 by the  
17  
18 Institutional Review Board of Beijing Tiantan Hospital Affiliated to Capital Medical  
19  
20 University (approval number KY2013-002-01). The study was registered on November  
21  
22 8, 2013 at the Chinese Clinical Trial Registry (ChiCTR-PRC-13003879).  
23  
24  
25  
26  
27

### 28 29 **Dissemination plan**

30  
31 Results of the trial will be submitted to international peer reviewed journal. Results will  
32  
33 also be presented at national and international conferences relevant to subject fields.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**TRIAL STATUS**

The patient recruitment began on January 6, 2014, and the first patient was enrolled on the same day. The study will be completed in December 2014.

For peer review only

## SUMMARY

Endotracheal extubation is a critical step during post-operative care in neurosurgical patients [9]. Pain is common during extubation period, and related to complications and adverse outcome [8]. Adequate analgesia is needed in this situation. Although revised Clinical Practice Guidelines from SCCM have recommended that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to potentially painful procedures [7], study for analgesia during endotracheal extubation is still limited. As a new opioid with minimal respiratory depression effect and a rapid onset and short duration of action, remifentanyl seems suitable for prophylactic analgesia during extubation in patients after craniotomy [13-16]. We want to provide such evidence in present study. Even a neutral result will provide important insight, as this would mean that more studies are needed to explore a safe and effective way of pain management during endotracheal extubation. This is the main strength of present study. There are some limitations to our study protocol. First, because there is no proven dose of remifentanyl which can prevent sedation and respiratory depression in a neurosurgical patient being weaned off ventilator, the dose of remifentanyl used in present study is arbitrary. Second, we assumed a 15% reduction in severe pain after the administration of remifentanyl in the calculation of sample size. There are no previous studies to support this. However, an effectivity of 15% is generally adopted in clinical studies.

## REFERENCES

1. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. *Anesthesiology* 2007;**106**:687-95.
2. Chanques G, Sebbane M, Barbotte E, et al. A prospective study of pain at rest: Incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. *Anesthesiology* 2007;**107**:858-60.
3. Robinson BR, Mueller EW, Henson K, et al. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. *J Trauma* 2008;**65**:517-26.
4. Payen JF, Bosson JL, Chanques G, et al. DOLOREA Investigators. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: A post Hoc analysis of the DOLOREA study. *Anesthesiology* 2009;**111**:1308-16.
5. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. *Crit Care Med* 2006;**34**:1691-9.
6. Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. *Am J Crit Care* 2001;**10**:238-51.
7. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine:



- 1  
2  
3  
4 Clinical practice guidelines for the management of pain, agitation, and delirium  
5  
6 in adult patients in the intensive care unit. *Crit Care Med* 2013;**41**:263-306.  
7  
8  
9 8. Gacouin A, Camus C, Le Tulzo Y, et al. Assessment of peri-extubation pain by  
10  
11 visual analogue scale in the adult intensive care unit: a prospective  
12  
13 observational study. *Intensive Care Med* 2004;**30**:1340-7.  
14  
15  
16 9. Difficult Airway Society Extubation Guidelines Group, Popat M, Mitchell V, et  
17  
18 al. Difficult Airway Society Guidelines for the management of tracheal  
19  
20 extubation. *Anaesthesia* 2012;**67**:318-40.  
21  
22  
23  
24 10. Cai YH, Zeng HY, Shi ZH, et al. Factors influencing delayed extubation after  
25  
26 infratentorial craniotomy for tumour resection: a prospective cohort study of  
27  
28 800 patients in a Chinese neurosurgical centre. *J Int Med Res* 2013;**41**:208-17.  
29  
30  
31 11. Cata JP, Saager L, Kurz A, et al. Successful extubation in the operating room  
32  
33 after infratentorial craniotomy: the Cleveland Clinic experience. *J Neurosurg*  
34  
35 *Anesthesiol* 2011;**23**:25-9.  
36  
37  
38  
39 12. Bruder N, Ravussin P. Recovery from anesthesia and postoperative extubation  
40  
41 of neurosurgical patients: a review. *J Neurosurg Anesthesiol* 1999;**11**:282-93.  
42  
43  
44 13. Glass PS, Gan TJ, Howell S. A review of the pharmacokinetics and  
45  
46 pharmacodynamics of remifentanil. *Anesth Analg* 1999;**89**(4 Suppl):S7-S14.  
47  
48  
49 14. Beers R, Camporesi E. Remifentanil update: clinical science and utility. *CNS*  
50  
51 *drugs* 2004;**18**:1085-104.  
52  
53  
54 15. Egan TD, Kern SE, Muir KT, et al. Remifentanil by bolus injection: a safety,  
55  
56 pharmacokinetic, pharmacodynamic, and age effect investigation in human  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- volunteers. *Br J Anaesth* 2004;**92**:335-43.
16. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanyl. *Crit Care* 2008;**12**(Suppl 3):S5.
17. Casey E, Lane A, Kuriakose D, et al. Bolus remifentanyl for chest drain removal in ICU: a randomized double-blind comparison of three modes of analgesia in post-cardiac surgical patients. *Intensive Care Med* 2010;**36**:1380-5.
18. Burlacu CL, McKeating K, McShane AJ. Remifentanyl for the insertion and removal of long-term central venous access during monitored anesthesia care. *J Clin Anesth* 2011;**23**:286-91.
19. Le Floch R, Naux E, Pilorget A, et al. Use of remifentanyl for analgesia during dressing change in spontaneously breathing non-intubated burn patients. *Ann Burns Fire Disasters* 2006;**19**:136-9.
20. Leone M, Albanese J, Viviani X, et al. The effects of remifentanyl on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients. *Anesth Analg* 2004;**99**:1193-8.
21. Kim SY, Yang SY, Na SW, et al. Low-dose remifentanyl infusion during ventilator weaning and tracheal extubation in postoperative intensive care unit patients sedated with propofol-remifentanyl: a randomised clinical trial. *Anaesth Intensive Care* 2012;**40**:656-62.
22. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanyl on intracranial pressure and cerebral blood flow velocity in patients with head trauma. *Acta Anaesthesiol Scand* 2004;**48**:396-9.

- 1  
2  
3  
4 23. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of  
5  
6 analgesia- based sedation using remifentanil versus standard hypnotic-based  
7  
8 regimens in intensive care unit patients with brain injuries: a randomised,  
9  
10 controlled trial [ISRCTN50308308]. Crit Care 2004;**8**:R268-R280.  
11  
12  
13  
14 24. Bauer C, Kreuer S, Ketter R, et al. Remifentanil-propofol versus  
15  
16 fentanyl-midazolam combina- tions for intracranial surgery: Influence of  
17  
18 anaesthesia tech- nique and intensive sedation on ventilation times and duration  
19  
20 of stay in the ICU. Anaesthetist 2007;**56**:128-32.  
21  
22  
23  
24  
25 25. Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg  
26  
27 Med 1996;**27**:427-32.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions**

YXW and JXZ participated in the design of the study and drafted the manuscript. HC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement**

The study was funded by Beijing Health Bureau (No: 2009-3-28). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

**Competing interests**

The authors declare that they have no competing interests.

**Table 1: Screening checklist used to determine the patient's suitability for extubation**

Question	Answer
1. Awake and alert with cerebral function adequate for patient co-operation or equivalent preoperative state of consciousness?	Yes/No
2. Hemodynamic stability (lack of vasopressor support and mean arterial pressure within 10-15% of baseline)?	Yes/No
3. Adequate recovery of muscle strength?	Yes/No
4. Normal tidal volumes, normocapnia (end-tidal carbon dioxide 30-45 mmHg), minimum pulse oximetry > 95% with FiO <sub>2</sub> 0.5?	Yes/No
5. Intact gag reflex and swallow function (presence of clearly audible cough during suctioning)?	Yes/No

The answer to all questions must be "yes" in order for extubation to be approved.

FiO<sub>2</sub>: fraction of inspired oxygen

1  
2  
3  
4 **Figure legend**  
5  
6

7 Figure 1: Trial schematic diagram  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7 **Short-term use of remifentanil during endotracheal extubation for prophylactic**  
8 **analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy**  
9 **Study): a study protocol and statistical analysis plan for a randomized controlled**  
10 **trial**  
11  
12  
13  
14

15  
16  
17  
18 Yuan-Xing Wu, Han Chen, Jian-Xin Zhou\*

19  
20 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical  
21 University, Beijing, 100050, China  
22  
23

24  
25  
26  
27 \*: Corresponding author

28  
29 Jian-Xin Zhou

30  
31 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical  
32 University  
33

34  
35 Address: No 6, Tiantan Xili, Dongcheng district, Beijing, 100050, China

36  
37 Telephone: +8610 67098019

38  
39 Email: zhoujx.cn@gmail.com  
40  
41  
42  
43

44  
45 Keywords: remifentanil, analgesia, prophylactic, extubation, craniotomy  
46  
47

48  
49 **Word count: 2569**  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

**ABSTRACT**

**Introduction:** Acute pain is common during endotracheal extubation period, and is related to complications and adverse outcomes. Patients with delayed extubation after craniotomy are vulnerable to pain and complications of extubation. However, pain control during extubation is still inadequate. Remifentanyl, a new opioid with rapid onset and short duration of action, provides adequate analgesia during procedures with minimal effect of respiratory depression.

**Methods and analysis:** The study is a prospective, randomized, double-blinded, controlled, parallel-group design. Patients with delayed extubation after intracranial surgery are screened daily. Adult patients ready for extubation are enrolled and assigned randomly to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Patients in Remi group receive intravenous bolus dose of remifentanyl 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride at a volume and rate equal to that of remifentanyl. Pain intensity is measured by visual analog scale (VAS) pain score. Adverse events during drug infusion are documented and reported. Patients will be followed up until hospital discharge, death or 60 days after the trial intervention, on first-served basis. Incidence of re-intubation and re-operation within 72 hours after extubation, length of stay in intensive care unit and hospital and mortality are collected. The primary endpoint is the incidence of severe pain (defined as VAS pain score more than 5 cm) during peri-extubation period (defined as the period of time from immediately before extubation to 20 minutes after

Formatted: Right: 0.25"



1  
2  
3  
4  
5  
6  
7 extubation).

8  
9 **Ethics and dissemination:** The study was approved by the IRB of Beijing Tiantan  
10 Hospital, Capital Medical University. Study findings will be disseminated through  
11 peer-reviewed publications and conference presentations.  
12  
13

14  
15 **Trial Registration:** ClinicalTrials (NCT): ChiCTR-PRC-13003879.  
16  
17

### 18 19 20 **Main strengths and limitations of the study**

21  
22 Pain is common during extubation period, and related to complications and adverse  
23 outcome. Adequate analgesia is needed in this situation. The main strength of the study  
24 is that we will provide the evidence of a new opioid (remifentanil) with minimal  
25 respiratory depression effect and a rapid onset and short duration of action, for  
26 prophylactic analgesia during extubation in patients after craniotomy.  
27  
28

29  
30 Other opioids may be suitable for prophylactic analgesia during extubation. The main  
31 limitation of the study is that we do not use other opioids, such as morphine or fentanyl,  
32 as control groups. Because there is no proven dose of remifentanil which can prevent  
33 sedation and respiratory depression in a neurosurgical patient being weaned off  
34 ventilator, the dose of remifentanyl used in present study is arbitrary.  
35  
36  
37

38  
39  
40  
41  
42 Formatted: Font: (Default) Times New Roman,  
12 pt

43  
44 Formatted: Font: (Default) Times New Roman,  
12 pt

45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56 Formatted: Right: 0.25"  
57  
58  
59  
60

## INTRODUCTION

Clinical epidemiology studies have shown that critically ill patients in intensive care unit (ICU) are at high-risk of pain, and inadequate treatment of pain is associated with adverse outcomes [1,2]. Appropriate analgesia, not only attenuates stress response resulted from pain, but also reduces the incidence of iatrogenic complications, shorten the duration of mechanical ventilation and length of stay (LOS) in ICU [3-5]. In addition to pain at rest, pain related to procedures is common in ICU patients, and inadequate treatment of procedural pain remains a significant problem for many patients [6]. The revised clinical practice guidelines for management of pain, agitation, and delirium from Society of Critical Care Medicine (SCCM) also recommend that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to chest tube removal and other types of potentially painful procedures, and suggest that intravenous opioids should be considered as the first-line drug class of choice [7]. Manipulation of artificial airway, especially endotracheal extubation is among the high pain-intensity procedures in ICU. By using the patient's self-report pain scale as pain evaluation method, Gacouin et al. found that 45% of patients experienced severe pain at the time of endotracheal extubation [8]. Acute pain during extubation is associated with sympathetic nervous system activation, which could result in respiratory and circulatory instability [9]. Therefore, it is reasonable to control pain and stress responses at the time of endotracheal extubation in some high-risk patients, such as those after intracranial surgery. It has been reported that the proportion of patients who underwent delayed extubation after craniotomy is about 10% to 50% [10,11]. These

Formatted: Right: 0.25"

1  
2  
3  
4  
5  
6  
7 patients are vulnerable to pain and complications of extubation [12]. On the other hand,  
8  
9 despite a greater awareness of pain during endotracheal extubation, clinicians remain  
10  
11 reluctant to administer opioids in patients following craniotomy. The major concern is  
12  
13 the side effects of respiratory depression and influence on consciousness of these drugs.  
14  
15 To our knowledge, up to now, no study has been published for adequate management of  
16  
17 pain during extubation in patients with delayed extubation after craniotomy.

18  
19 Remifentanyl is a potent synthetic selective  $\mu$ -opioid receptor agonist with a rapid onset  
20  
21 and short duration of action, regardless of the duration of its administration [13,14].  
22  
23

24 Remifentanyl differs from other synthetic opioids in its metabolism by non-specific  
25  
26 plasma and tissue esterases. Study in human volunteers has shown that the respiratory  
27  
28 depression of remifentanyl by bolus injection is mild and easily treated with requests to  
29  
30 breathe or the administration of oxygen [15]. These pharmacological properties suggest  
31  
32 that remifentanyl could be a potentially safe and effective analgesic in clinical situations  
33  
34 requiring a brief period of intense control of pain, such as painful procedures in ICU  
35  
36 [16]. There have been reported remifentanyl used as prophylactic analgesia during  
37  
38 removal of chest drain [17], insertion and removal of long-term central venous access  
39  
40 [18], dressing change [19], and endotracheal suctioning [20]. However, although a  
41  
42 plenty of studies have shown that the remifentanyl facilitates emergency in general  
43  
44 anesthesia and weaning process in mechanical ventilation [14,16,21], study for  
45  
46 prophylactic use of remifentanyl in endotracheal extubation is limited.  
47  
48

49  
50 There has been increased interest in use of remifentanyl in brain injured patients. In  
51  
52 patients with traumatic brain injury, it has been demonstrated that remifentanyl has no  
53  
54

55  
56  
57  
58  
59  
60  
Formatted: Right: 0.25"

1  
2  
3  
4  
5  
6  
7 significant changes in systematic and cerebral hemodynamics, such as intracranial  
8  
9 pressure, mean blood pressure, cerebral perfusion pressure, and cerebral blood flow  
10  
11 velocity [22]. Several studies also compared remifentanyl with fentanyl or morphine as  
12  
13 analgesic in neurologic ICU patients. A randomized multicenter study in patients with  
14  
15 brain injury showed that mean neurologic assessment times were significantly shorter  
16  
17 with remifentanyl than with fentanyl or with morphine, and patients were extubated  
18  
19 significantly faster after remifentanyl than after morphine [23]. Another retrospective  
20  
21 study investigated patients with delayed extubation after brain tumor surgery, and  
22  
23 found that mean extubation times were significantly shorter after remifentanyl/propofol  
24  
25 than after fentanyl/midazolam, and LOS in ICU was significantly reduced [24]. These  
26  
27 results indicate that the rapid metabolism and lack of accumulation of remifentanyl  
28  
29 facilitate faster waking and neurological assessment, and suggest that remifentanyl  
30  
31 might be a better choice of analgesic in patients with brain injury.  
32  
33  
34

35  
36 In present study, remifentanyl is used as prophylactic analgesics in patients with delayed  
37  
38 extubation after craniotomy. The aim is to evaluate the efficacy and safety of  
39  
40 remifentanyl for control of pain and stress responses due to extubation. The primary  
41  
42 hypothesis is that prophylactic use of remifentanyl will reduce the incidence of severe  
43  
44 pain during endotracheal extubation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

## METHODS AND ANALYSIS

### Study design overview

The present study is a prospective, single-center, randomized, double-blinded, placebo-controlled, two-arm trial in patients with delayed extubation after craniotomy. Trial schematic diagram is shown in Figure 1.

### Study setting and population

The study setting is neurosurgical ICU (30 beds), Beijing Tiantan Hospital (1100 beds), Capital Medical University, Beijing, China.

All patients after intracranial surgery with delayed extubation admitted to our ICU are screened daily for study eligibility.

Inclusion criteria are:

- 1) Age between 18-65 years-old;
- 2) Within 72 hours after operation;
- 3) Awaken and able to cope with the assessment of visual analog scale (VAS) pain score;
- 4) Ready for extubation after evaluated by neurosurgeon and ICU physician in charge.

Exclusion criteria are:

- 1) Operation relating to medulla oblongata region;
- 2) Hepatic Insufficiency;

Formatted: Right: 0.25"

- 3) Renal insufficiency;
- 4) Pregnant or lactating women;
- 5) Need continuous infusion of vasopressor before the start of study drug infusion;
- 6) Chronic opioid use over three months;
- 7) Known opioids allergy;
- 8) Readmitted to ICU after randomization to the study;
- 9) Enrolled in another trial.

Patient's endotracheal tube is extubated at the discretion of neurosurgeon and ICU physician in charge of the patient. Neurosurgeon and ICU physician discuss the patient's status and evaluate the patient by a screen checklist (Table 1) [10]. When answers of all items in checklist are "yes", the patient is ready for extubation. At this time, a 24-hour on-call study coordinator will be informed immediately, and patient's eligibility for the study is evaluated and confirmed.

#### **Randomization, double-blind and allocation concealment**

The study has a prospective, randomized, double-blinded, controlled, parallel-group design. Consecutive patients are randomly assigned to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Randomization is based on computer generated random digits table and follows a concealed process using sealed and numbered envelopes that allocate the patient to either of the two arms of the study. Patients may be randomized into this study only once unless they were discharged from the hospital and were re-admitted beyond 180 days of the first enrollment. The study

Formatted: Right: 0.25"

8

1  
2  
3  
4  
5  
6  
7 does not allow cross-over and, if any occur, they will be reported as protocol violations.

8  
9 Experimental drug and placebo with the same character are prepared by a pharmacist.

10  
11 Patients and all study personnel except the investigative pharmacist are blind to  
12  
13 treatment assignment. The details of the series are unknown to any of the investigators  
14  
15 and are contained in a set of opaque and sealed envelopes, each bearing on the outside  
16  
17 only the number.  
18  
19

### 20 21 22 **Data collected at study entry**

23  
24 At baseline, data on demographic, history of past illness characteristics and diagnosis  
25  
26 of the patients are obtained. The surgical site, operation time, use of sedatives and  
27  
28 analgesics during anaesthesia and ICU stay, time of mechanical ventilation,  
29  
30 formulation and dose of postoperative patient-control-analgesia (PCA) pump, and time  
31  
32 between end of operation and study drug infusion are recorded. Acute Physiology and  
33  
34 Chronic Health Evaluation II score (APACHE II) is calculated.  
35  
36  
37  
38  
39

### 40 41 **Trial interventions**

42  
43 All patients are randomized 1:1 to receive remifentanyl (Remi group) or placebo (Saline  
44  
45 group) infusion. Patients in Remi group receive intravenous bolus dose of remifentanyl  
46  
47 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20  
48  
49 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride  
50  
51 at a volume and rate equal to that of remifentanyl. Study drugs are administered by  
52  
53 using syringe pump.  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

1  
2  
3  
4  
5  
6  
7 Immediately after drug infusion, ICU physician evaluate the patient by using  
8  
9 extubation screen checklist shown in Table 1. If the patient passes the evaluation,  
10  
11 endotracheal extubation will be carried out immediately by registered ICU nurses. The  
12  
13 patient will be labeled as “failing to pass extubation test after drug administration” if he  
14  
15 or she does not pass the evaluation. The reason of test failure will be documented. The  
16  
17 patient will be re-evaluated every hour thereafter, and data about extubation will be  
18  
19 documented.  
20

21  
22 Vital signs, which including heart rate (HR), respiratory rate (RR), non-invasive blood  
23  
24 pressure (BP) and pulse oxygen saturation (SpO<sub>2</sub>), are continuously monitored. VAS  
25  
26 pain score is used to measure the pain intensity by the study investigator [25]. Each  
27  
28 patient is instructed and asked to point to a mark on a 10-cm horizontal line labelled  
29  
30 with descriptors of pain intensity (‘No pain’ at the 0 cm point and ‘Extreme pain’ at the  
31  
32 10 cm point). VAS and vital signs (HR, RR, BP and SpO<sub>2</sub>) are documented at four time  
33  
34 points: before drug infusion (baseline), immediately before extubation, immediately to  
35  
36 3 minutes after extubation and 20 minutes after extubation.  
37  
38

39  
40 Patients will be followed up until hospital discharge, death or 60 days after the trial  
41  
42 intervention, on first-served basis. Following data are collected: incidence of  
43  
44 re-intubation within 72 hours after extubation, incidence of re-operation due to  
45  
46 intracranial hemorrhage or edema within 72 hours after extubation, LOS in ICU and  
47  
48 hospital and mortality.  
49  
50

#### 51 52 53 **Adverse events management and emergency stop of the study drug** 54

55  
56  
57  
58  
59  
60  
10 Formatted: Right: 0.25"



1  
2  
3  
4  
5  
6  
7 Patients are closely monitored during study drug infusion. Taking into account the  
8  
9 potential adverse effects of remifentanyl, experimental drugs must be immediately  
10  
11 terminated when the following occurs:  
12

- 13 1) Unresponsive to calling and patting on the shoulder;
- 14 2) RR less than 8 respirations per minute and SpO<sub>2</sub> less than 92%;
- 15 3) HR less than 50 beats per minute after atropine in 0.25 mg bolus;
- 16 4) Systolic BP less than 90 mmHg;
- 17 5) Serious allergic reaction such as throat swelling, bronchospasm or skin rash.

18  
19  
20 These data will be documented and reported as adverse events.  
21  
22  
23  
24

### 25 26 27 28 29 **Study endpoints**

30  
31 The primary endpoint of present study is the incidence of severe pain during  
32  
33 peri-extubation period. Peri-extubation is defined as the period of time from  
34  
35 immediately before extubation to 20 minutes after extubation. Severe pain is defined as  
36  
37 one of the VAS pain scores is more than 5 cm.  
38

39  
40 Secondary endpoints include:  
41

- 42 1) VAS pain score and vital signs (HR, RR, BP and SpO<sub>2</sub>) during peri-extubation  
43  
44 period;
- 45 2) Incidence of failing to pass extubation evaluation after experimental drug  
46  
47 infusion;
- 48 3) Incidence of re-intubation within 72 hours after extubation;
- 49 4) Incidence of re-operation due to intracranial hemorrhage or edema within 72  
50  
51  
52  
53  
54

55  
56  
57  
58  
59  
60  
11  
Formatted: Right: 0.25"

1  
2  
3  
4  
5  
6  
7 hours after extubation;

- 8  
9 5) Incidence of adverse events during experimental drug infusion;  
10  
11 6) LOS in ICU and hospital;  
12  
13 7) Mortality.  
14  
15

### 16 17 18 **Current sample size justification**

19  
20 Primarily, we expect the incidence of severe pain during peri-extubation period to  
21  
22 decrease after remifentanyl infusion in delayed extubation patients after craniotomy.  
23  
24 Previous investigation showed that severe peri-extubation pain was occurred in 45% of  
25  
26 patients [8]. It is expected that the incidence of severe pain would decrease to 30% after  
27  
28 remifentanyl infusion. Using the Power and Sample Size Calculation program, we will  
29  
30 need to study 74 experimental subjects and 74 control subjects to be able to reject the  
31  
32 null hypothesis that the population means of the experimental and control groups are  
33  
34 equal with a probability (power) of 0.8. The Type I error probability with testing this  
35  
36 null hypothesis is 0.05.  
37  
38  
39  
40  
41

### 42 **Statistical analysis**

43  
44 All analyses will be according to the intention-to-treat principle, that is, all randomized  
45  
46 patients will be analyzed in the groups to which they were originally allocated and will  
47  
48 be blinded to treatment assignment.  
49

50  
51 Baseline characteristics will be summarized by univariate analyses. Categorical  
52  
53 variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test.  
54  
55

56  
57  
58  
59  
60  
12 Formatted: Right: 0.25"

1  
2  
3  
4  
5  
6  
7 Continuous variables will be checked for normal distribution and presented as mean  
8  
9 and standard deviation or median and interquartile range as appropriate. Comparison of  
10  
11 continuous variables will be performed by using Student's t-test for normally  
12  
13 distributed variables and the Mann-Whitney U test for non-normally distributed  
14  
15 variables.  
16

17  
18 We use repeated measure of analysis of variance (ANOVA) for comparing VAS pain  
19  
20 score and vital signs (HR, RR, BP and SpO<sub>2</sub>) across different time points (before drug  
21  
22 infusion and during peri-extubation period) between the two groups.  
23

24 All tests of significance will be at the 5% significance level, and two-sided. Analyses  
25  
26 are conducted by using SPSS 17.0.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

13

## ETHICS AND DISSEMINATION

### Ethical aspects and informed consent

Patients with delayed extubation after craniotomy are often unable to provide consent before extubation. After patient's eligibility for the study is confirmed, the ICU physician will introduce the family to the study coordinator. The physician will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program that is being conducted, and that this person is qualified to do so. The study coordinator will take the family to a place where they can talk confidentially. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand.

The study coordinator will explain that the patient may experience pain during extubation and, if so, the patient could become worse. The coordinator will say that a new opioid drug, remifentanyl provides adequate analgesia with minimal respiratory depression. He (or she) will explain that in a small percentage of patients, remifentanyl could cause bradycardia, hypotension and respiratory depression. The potential advantages of using or not using remifentanyl will be described. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study

Formatted: Right: 0.25"

14

1  
2  
3  
4  
5  
6  
7 coordinator, local co-investigator and the local Ethical Committee. Written consent will  
8  
9 be obtained in the presence of a witness.

10  
11 A register is kept of all patients evaluated for inclusion and of patients who withdraw  
12  
13 from the study. The latter are clinically followed up without their data being analyzed in  
14  
15 the study.

16  
17  
18 The study protocol and consent forms were approved on November 1, 2013 by the  
19  
20 Institutional Review Board of Beijing Tiantan Hospital Affiliated to Capital Medical  
21  
22 University (approval number KY2013-002-01). The study was registered on November  
23  
24 8, 2013 at the Chinese Clinical Trial Registry (ChiCTR-PRC-13003879).  
25  
26  
27

### 28 29 **Dissemination plan**

30  
31 Results of the trial will be submitted to international peer reviewed journal. Results will  
32  
33 also be presented at national and international conferences relevant to subject fields.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

15

**TRIAL STATUS**

The patient recruitment began on January 6, 2014, and the first patient was enrolled  
on January 06, 2014 the same day. The study will be completed in December 2014.

Formatted: Font: (Default) Times New Roman, 12 pt

For peer review only

Formatted: Right: 0.25"

16

## SUMMARY

Endotracheal extubation is a critical step during post-operative care in neurosurgical patients [9]. Pain is common during extubation period, and related to complications and adverse outcome [8]. Adequate analgesia is needed in this situation. Although revised Clinical Practice Guidelines from SCCM have recommended that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to potentially painful procedures [7], study for analgesia during endotracheal extubation is still limited. As a new opioid with minimal respiratory depression effect and a rapid onset and short duration of action, remifentanyl seems suitable for prophylactic analgesia during extubation in patients after craniotomy [13-16]. We want to provide such evidence in present study. Even a neutral result will provide important insight, as this would mean that more studies are needed to explore a safe and effective way of pain management during endotracheal extubation. This is the main strength of present study. There are some limitations to our study protocol. First, because there is no proven dose of remifentanyl which can prevent sedation and respiratory depression in a neurosurgical patient being weaned off ventilator, the dose of remifentanyl used in present study is arbitrary. Second, we assumed a 15% reduction in severe pain after the administration of remifentanyl in the calculation of sample size. There are no previous studies to support this. However, an effectivity of 15% is generally adopted in clinical studies.

Formatted: Right: 0.25"

17

## REFERENCES

1. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. *Anesthesiology* 2007;**106**:687-95.
2. Chanques G, Sebbane M, Barbotte E, et al. A prospective study of pain at rest: Incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. *Anesthesiology* 2007;**107**:858-60.
3. Robinson BR, Mueller EW, Henson K, et al. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. *J Trauma* 2008;**65**:517-26.
4. Payen JF, Bosson JL, Chanques G, et al. DOLOREA Investigators. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: A post Hoc analysis of the DOLOREA study. *Anesthesiology* 2009;**111**:1308-16.
5. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. *Crit Care Med* 2006;**34**:1691-9.
6. Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. *Am J Crit Care* 2001;**10**:238-51.
7. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine:

Formatted: Right: 0.25"

18



- 1  
2  
3  
4  
5  
6  
7 Clinical practice guidelines for the management of pain, agitation, and delirium  
8  
9 in adult patients in the intensive care unit. *Crit Care Med* 2013;**41**:263-306.
- 10  
11 8. Gacouin A, Camus C, Le Tulzo Y, et al. Assessment of peri-extubation pain by  
12  
13 visual analogue scale in the adult intensive care unit: a prospective  
14  
15 observational study. *Intensive Care Med* 2004;**30**:1340-7.
- 16  
17  
18 9. Difficult Airway Society Extubation Guidelines Group, Popat M, Mitchell V, et  
19  
20 al. Difficult Airway Society Guidelines for the management of tracheal  
21  
22 extubation. *Anaesthesia* 2012;**67**:318-40.
- 23  
24  
25 10. Cai YH, Zeng HY, Shi ZH, et al. Factors influencing delayed extubation after  
26  
27 infratentorial craniotomy for tumour resection: a prospective cohort study of  
28  
29 800 patients in a Chinese neurosurgical centre. *J Int Med Res* 2013;**41**:208-17.
- 30  
31  
32 11. Cata JP, Saager L, Kurz A, et al. Successful extubation in the operating room  
33  
34 after infratentorial craniotomy: the Cleveland Clinic experience. *J Neurosurg*  
35  
36 *Anesthesiol* 2011;**23**:25-9.
- 37  
38  
39 12. Bruder N, Ravussin P. Recovery from anesthesia and postoperative extubation  
40  
41 of neurosurgical patients: a review. *J Neurosurg Anesthesiol* 1999;**11**:282-93.
- 42  
43  
44 13. Glass PS, Gan TJ, Howell S. A review of the pharmacokinetics and  
45  
46 pharmacodynamics of remifentanyl. *Anesth Analg* 1999;**89**(4 Suppl):S7-S14.
- 47  
48  
49 14. Beers R, Camporesi E. Remifentanyl update: clinical science and utility. *CNS*  
50  
51 *drugs* 2004;**18**:1085-104.
- 52  
53  
54 15. Egan TD, Kern SE, Muir KT, et al. Remifentanyl by bolus injection: a safety,  
55  
56 pharmacokinetic, pharmacodynamic, and age effect investigation in human  
57  
58  
59  
60

Formatted: Right: 0.25"

19

- 1  
2  
3  
4  
5  
6  
7 volunteers. *Br J Anaesth* 2004;**92**:335-43.
- 8  
9 16. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on  
10 remifentanil. *Crit Care* 2008;**12**(Suppl 3):S5.
- 11  
12  
13 17. Casey E, Lane A, Kuriakose D, et al. Bolus remifentanil for chest drain removal  
14 in ICU: a randomized double-blind comparison of three modes of analgesia in  
15 post-cardiac surgical patients. *Intensive Care Med* 2010;**36**:1380-5.
- 16  
17  
18  
19 18. Burlacu CL, McKeating K, McShane AJ. Remifentanil for the insertion and  
20 removal of long-term central venous access during monitored anesthesia care. *J*  
21 *Clin Anesth* 2011;**23**:286-91.
- 22  
23  
24  
25 19. Le Floch R, Naux E, Pilorget A, et al. Use of remifentanil for analgesia during  
26 dressing change in spontaneously breathing non-intubated burn patients. *Ann*  
27 *Burns Fire Disasters* 2006;**19**:136-9.
- 28  
29  
30  
31 20. Leone M, Albanese J, Viviani X, et al. The effects of remifentanil on  
32 endotracheal suctioning-induced increases in intracranial pressure in  
33 head-injured patients. *Anesth Analg* 2004;**99**:1193-8.
- 34  
35  
36  
37 21. Kim SY, Yang SY, Na SW, et al. Low-dose remifentanil infusion during  
38 ventilator weaning and tracheal extubation in postoperative intensive care unit  
39 patients sedated with propofol-remifentanil: a randomised clinical trial. *Anaesth*  
40 *Intensive Care* 2012;**40**:656-62.
- 41  
42  
43  
44 22. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanil on intracranial  
45 pressure and cerebral blood flow velocity in patients with head trauma. *Acta*  
46 *Anaesthesiol Scand* 2004;**48**:396-9.
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

20

- 1  
2  
3  
4  
5  
6  
7 23. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of  
8  
9 analgesia- based sedation using remifentanil versus standard hypnotic-based  
10  
11 regimens in intensive care unit patients with brain injuries: a randomised,  
12  
13 controlled trial [ISRCTN50308308]. Crit Care 2004;**8**:R268-R280.  
14  
15  
16 24. Bauer C, Kreuer S, Ketter R, et al. Remifentanil-propofol versus  
17  
18 fentanyl-midazolam combina- tions for intracranial surgery: Influence of  
19  
20 anaesthesia tech- nique and intensive sedation on ventilation times and duration  
21  
22 of stay in the ICU. Anaesthetist 2007;**56**:128-32.  
23  
24  
25  
26 25. Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg  
27  
28 Med 1996;**27**:427-32.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Right: 0.25"

21

**Authors' contributions**

YXW and JXZ participated in the design of the study and drafted the manuscript. HC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement**

The study was funded by Beijing Health Bureau (No: 2009-3-28). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

**Competing interests**

The authors declare that they have no competing interests.

Formatted: Right: 0.25"

22

**Table 1: Screening checklist used to determine the patient's suitability for****extubation**

Question	Answer
1. Awake and alert with cerebral function adequate for patient co-operation or equivalent preoperative state of consciousness?	Yes/No
2. Hemodynamic stability (lack of vasopressor support and mean arterial pressure within 10-15% of baseline)?	Yes/No
3. Adequate recovery of muscle strength?	Yes/No
4. Normal tidal volumes, normocapnia (end-tidal carbon dioxide 30-45 mmHg), minimum pulse oximetry > 95% with FiO <sub>2</sub> 0.5?	Yes/No
5. Intact gag reflex and swallow function (presence of clearly audible cough during suctioning)?	Yes/No

The answer to all questions must be "yes" in order for extubation to be approved.

FiO<sub>2</sub>: fraction of inspired oxygen

Formatted: Right: 0.25"

23

1  
2  
3  
4  
5  
6  
7 **Figure legend**  
8


9  
10 Figure 1: Trial schematic diagram  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Formatted: Right: 0.25"

24

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



111x90mm (300 x 300 DPI)

Peer Review Only



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4-6
	2b	Specific objectives or hypotheses	6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7, 9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Not applicable
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	9-11
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	11-12
	6b	Any changes to trial outcomes after the trial commenced, with reasons	Not applicable
Sample size	7a	How sample size was determined	12
	7b	When applicable, explanation of any interim analyses and stopping guidelines	Not applicable
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	8-9
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8-9
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8-9
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8-9
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9



1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	8-9
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	12-13
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	Not applicable
7			
8	<b>Results</b>		
9	Participant flow (a diagram is strongly recommended)	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Not applicable in items 13a to 22
10			
11			
12		13b For each group, losses and exclusions after randomisation, together with reasons	
13	Recruitment	14a Dates defining the periods of recruitment and follow-up	
14		14b Why the trial ended or was stopped	
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
17			
18	Outcomes and estimation	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
19		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
20	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
21			
22	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
23			
24	<b>Discussion</b>		
25	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
26	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	
27	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
28			
29	<b>Other information</b>		
30	Registration	23 Registration number and name of trial registry	ChiCTR-PRC-13003879
31			
32	Protocol	24 Where the full trial protocol can be accessed, if available	Not applicable
33	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	The study was supported by Beijing Health
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44	CONSORT 2010 checklist		Page 2
45			
46			
47			
48			
49			

---

Bureau (No: 2009-3-28).  
The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

---

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

# BMJ Open

**Short-term use of remifentanyl during endotracheal extubation for prophylactic analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy Study): a study protocol and statistical analysis plan for a randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005635.R2
Article Type:	Protocol
Date Submitted by the Author:	11-Sep-2014
Complete List of Authors:	Wu, Yuan-Xing; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine Chen, Han; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine Zhou, Jian-Xin; Beijing Tiantan Hospital, Capital Medical University, Department of Critical Care Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Intensive care, Neurology
Keywords:	Anaesthesia in neurology < ANAESTHETICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Adult intensive & critical care < ANAESTHETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Short-term use of remifentanil during endotracheal extubation for prophylactic**  
5  
6 **analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy**  
7  
8 **Study): a study protocol and statistical analysis plan for a randomized controlled**  
9  
10 **trial**  
11  
12

13  
14  
15  
16 Yuan-Xing Wu, Han Chen, Jian-Xin Zhou\*

17  
18 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical

19  
20 University, Beijing, 100050, China  
21  
22

23  
24  
25  
26 \*: Corresponding author  
27

28  
29 Jian-Xin Zhou

30  
31 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical

32  
33 University  
34

35  
36 Address: No 6, Tiantan Xili, Dongcheng district, Beijing, 100050, China  
37

38  
39 Telephone: +8610 67098019  
40

41  
42 Email: zhoujx.cn@gmail.com  
43  
44

45  
46 Keywords: remifentanil, analgesia, prophylactic, extubation, craniotomy  
47  
48

49  
50  
51 Word count: 4409  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Acute pain is common during endotracheal extubation period, and is related to complications and adverse outcomes. Patients with delayed extubation after craniotomy are vulnerable to pain and complications of extubation. However, pain control during extubation is still inadequate. Remifentanyl, a new opioid with rapid onset and short duration of action, provides adequate analgesia during procedures with minimal effect of respiratory depression.

**Methods and analysis:** The study is a prospective, randomized, double-blinded, controlled, parallel-group design. Patients with delayed extubation after intracranial surgery are screened daily. Adult patients ready for extubation are enrolled and assigned randomly to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Patients in Remi group receive intravenous bolus dose of remifentanyl 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride at a volume and rate equal to that of remifentanyl. Pain intensity is measured by visual analog scale (VAS) pain score. Adverse events during drug infusion are documented and reported. Patients will be followed up until hospital discharge, death or 60 days after the trial intervention, on first-served basis. Incidence of re-intubation and re-operation within 72 hours after extubation, length of stay in intensive care unit and hospital and mortality are collected. The primary endpoint is the incidence of severe pain (defined as VAS pain score more than 5 cm) during peri-extubation period (defined as the period of time from immediately before extubation to 20 minutes after

1  
2  
3  
4 extubation).

5  
6 **Ethics and dissemination:** The study was approved by the IRB of Beijing Tiantan  
7  
8 Hospital, Capital Medical University. Study findings will be disseminated through  
9  
10 peer-reviewed publications and conference presentations.  
11  
12

13  
14 **Trial Registration:** ClinicalTrials (NCT): ChiCTR-PRC-13003879.  
15  
16

### 17 18 19 **Main strengths and limitations of the study**

20  
21 Pain is common during extubation period, and related to complications and adverse  
22  
23 outcome. Adequate analgesia is needed in this situation. The main strength of the study  
24  
25 is that we will provide the evidence of a new opioid (remifentanyl) with minimal  
26  
27 respiratory depression effect and a rapid onset and short duration of action, for  
28  
29 prophylactic analgesia during extubation in patients after craniotomy.  
30  
31

32  
33 Pain management is a comprehensive algorithm, which includes pharmacologic and  
34  
35 non-pharmacologic interventions. In present study, only remifentanyl is investigated for  
36  
37 prophylactic analgesia during extubation. This is the main limitation of the study.  
38  
39

40  
41 Because there is no proven dose of remifentanyl which can prevent sedation and  
42  
43 respiratory depression in a neurosurgical patient being weaned off ventilator, the dose  
44  
45 of remifentanyl used in present study is arbitrary. The evaluation of visual analog scale  
46  
47 requires the patient's ability to self-report clearly, and this may limit the patient  
48  
49 population eligible for the present study. So, the results of this study will not be applied  
50  
51 to all patients after craniotomy, especially for those with consciousness impairments.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Clinical epidemiology studies have shown that critically ill patients in intensive care unit (ICU) are at high-risk of pain, and inadequate treatment of pain is associated with adverse outcomes [1,2]. Appropriate analgesia, not only attenuates stress response resulted from pain, but also reduces the incidence of iatrogenic complications, shorten the duration of mechanical ventilation and length of stay (LOS) in ICU [3-5]. In addition to pain at rest, pain related to procedures is common in ICU patients, and inadequate treatment of procedural pain remains a significant problem for many patients [6]. The revised clinical practice guidelines for management of pain, agitation, and delirium from Society of Critical Care Medicine (SCCM) also recommend that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to chest tube removal and other types of potentially painful procedures, and suggest that intravenous opioids should be considered as the first-line drug class of choice [7]. Manipulation of artificial airway, especially endotracheal extubation is among the high pain-intensity procedures in ICU. By using the patient's self-report pain scale as pain evaluation method, Gacouin et al. found that 45% of patients experienced severe pain at the time of endotracheal extubation [8]. Acute pain during extubation is associated with sympathetic nervous system activation, which could result in respiratory and circulatory instability [9]. Therefore, it is reasonable to control pain and stress responses at the time of endotracheal extubation in some high-risk patients, such as those after intracranial surgery. It has been reported that the proportion of patients who underwent delayed extubation after craniotomy is about 10% to 50% [10,11]. These

1  
2  
3  
4 patients are vulnerable to pain and complications of extubation [12]. On the other hand,  
5  
6 despite a greater awareness of pain during endotracheal extubation, clinicians remain  
7  
8 reluctant to administer opioids in patients following craniotomy. The major concern is  
9  
10 the side effects of respiratory depression and influence on consciousness of these drugs.  
11  
12 To our knowledge, up to now, no study has been published for adequate management of  
13  
14 pain during extubation in patients with delayed extubation after craniotomy.  
15  
16

17  
18 Remifentanyl is a potent synthetic selective  $\mu$ -opioid receptor agonist with a rapid onset  
19  
20 and short duration of action, regardless of the duration of its administration [13,14].  
21  
22

23  
24 Remifentanyl differs from other synthetic opioids in its metabolism by non-specific  
25  
26 plasma and tissue esterases. Study in human volunteers has shown that the respiratory  
27  
28 depression of remifentanyl by bolus injection is mild and easily treated with requests to  
29  
30 breathe or the administration of oxygen [15]. These pharmacological properties suggest  
31  
32 that remifentanyl could be a potentially safe and effective analgesic in clinical situations  
33  
34 requiring a brief period of intense control of pain, such as painful procedures in ICU  
35  
36 [16]. There have been reported remifentanyl used as prophylactic analgesia during  
37  
38 removal of chest drain [17], insertion and removal of long-term central venous access  
39  
40 [18], dressing change [19], and endotracheal suctioning [20]. However, although a  
41  
42 plenty of studies have shown that the remifentanyl facilitates emergency in general  
43  
44 anesthesia and weaning process in mechanical ventilation [14,16,21], study for  
45  
46 prophylactic use of remifentanyl in endotracheal extubation is limited.  
47  
48

49  
50 There has been increased interest in use of remifentanyl in brain injured patients. In  
51  
52 patients with traumatic brain injury, it has been demonstrated that remifentanyl has no  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 significant changes in systematic and cerebral hemodynamics, such as intracranial  
5  
6 pressure, mean blood pressure, cerebral perfusion pressure, and cerebral blood flow  
7  
8 velocity [22]. Several studies also compared remifentanyl with fentanyl or morphine as  
9  
10 analgesic in neurologic ICU patients. A randomized multicenter study in patients with  
11  
12 brain injury showed that mean neurologic assessment times were significantly shorter  
13  
14 with remifentanyl than with fentanyl or with morphine, and patients were extubated  
15  
16 significantly faster after remifentanyl than after morphine [23]. Another retrospective  
17  
18 study investigated patients with delayed extubation after brain tumor surgery, and  
19  
20 found that mean extubation times were significantly shorter after remifentanyl/propofol  
21  
22 than after fentanyl/midazolam, and LOS in ICU was significantly reduced [24]. These  
23  
24 results indicate that the rapid metabolism and lack of accumulation of remifentanyl  
25  
26 facilitate faster waking and neurological assessment, and suggest that remifentanyl  
27  
28 might be a better choice of analgesic in patients with brain injury.  
29  
30  
31  
32  
33  
34

35  
36 In present study, remifentanyl is used as prophylactic analgesics in patients with delayed  
37  
38 extubation after craniotomy. The aim is to evaluate the efficacy and safety of  
39  
40 remifentanyl for control of pain and stress responses due to extubation. The primary  
41  
42 hypothesis is that prophylactic use of remifentanyl will reduce the incidence of severe  
43  
44 pain during endotracheal extubation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

### Study design overview

The present study is a prospective, single-center, randomized, double-blinded, placebo-controlled, two-arm trial in patients with delayed extubation after craniotomy.

Trial schematic diagram is shown in Figure 1.

### Study setting and population

The study setting is neurosurgical ICU (30 beds), Beijing Tiantan Hospital (1100 beds), Capital Medical University, Beijing, China.

All patients after intracranial surgery with delayed extubation admitted to our ICU are screened daily for study eligibility.

Inclusion criteria are:

- 1) Age between 18-65 years-old;
- 2) Within 72 hours after operation;
- 3) Awaken and able to cope with the assessment of visual analog scale (VAS) pain score;
- 4) Ready for extubation after evaluated by neurosurgeon and ICU physician in charge.

Exclusion criteria are:

- 1) Operation relating to medulla oblongata region;
- 2) Hepatic Insufficiency;

- 3) Renal insufficiency;
- 4) Pregnant or lactating women;
- 5) Need continuous infusion of vasopressor before the start of study drug infusion;
- 6) Chronic opioid use over three months;
- 7) Known opioids allergy;
- 8) Readmitted to ICU after randomization to the study;
- 9) Enrolled in another trial.

Patient's endotracheal tube is extubated at the discretion of neurosurgeon and ICU physician in charge of the patient. Neurosurgeon and ICU physician discuss the patient's status and evaluate the patient by a screen checklist (Table 1) [10]. When answers of all items in checklist are "yes", the patient is ready for extubation. At this time, a 24-hour on-call study coordinator will be informed immediately, and patient's eligibility for the study is evaluated and confirmed.

#### **Randomization, double-blind and allocation concealment**

The study has a prospective, randomized, double-blinded, controlled, parallel-group design. Randomization is based on computer generated random digits table. The allocation sequence is sealed in numbered and opaque envelopes to ensure that the sequence is concealed. Enrolled patients are randomly assigned 1:1 to receive remifentanyl (labeled as Remi group) or placebo (labeled as Saline group) infusion. Patients may be randomized into this study only once unless they were discharged from the hospital and were re-admitted beyond 180 days of the first enrollment. The study

1  
2  
3  
4 does not allow cross-over and, if any occur, they will be reported as protocol violations.  
5  
6 Experimental drug and placebo with the same character are prepared by a pharmacist.  
7  
8  
9 Patients and all study personnel except the investigative pharmacist are blind to  
10  
11 treatment assignment. The details of the series are unknown to any of the investigators  
12  
13 and are contained in a set of opaque and sealed envelopes, each bearing on the outside  
14  
15 only the number.  
16  
17  
18  
19  
20

### 21 **Data collected at study entry**

22  
23 At baseline, data on demographic, history of past illness characteristics and diagnosis  
24  
25 of the patients are obtained. The surgical site, operation time, use of sedatives and  
26  
27 analgesics during anaesthesia and ICU stay, time of mechanical ventilation,  
28  
29 formulation and dose of postoperative patient-control-analgesia (PCA) pump, and time  
30  
31 between end of operation and study drug infusion are recorded. Acute Physiology and  
32  
33 Chronic Health Evaluation II score (APACHE II) is calculated.  
34  
35  
36  
37  
38  
39  
40

### 41 **Trial interventions**

42  
43 All patients are randomized 1:1 to receive remifentanyl (Remi group) or placebo (Saline  
44  
45 group) infusion. Patients in Remi group receive intravenous bolus dose of remifentanyl  
46  
47 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20  
48  
49 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride  
50  
51 at a volume and rate equal to that of remifentanyl. Study drugs are administered by  
52  
53 using syringe pump.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Immediately after drug infusion, ICU physician evaluate the patient by using  
5  
6 extubation screen checklist shown in Table 1. If the patient passes the evaluation,  
7  
8 endotracheal extubation will be carried out immediately by registered ICU nurses. The  
9  
10 patient will be labeled as “failing to pass extubation test after drug administration” if he  
11  
12 or she does not pass the evaluation. The reason of test failure will be documented. The  
13  
14 patient will be re-evaluated every hour thereafter, and data about extubation will be  
15  
16 documented.  
17  
18  
19

20  
21 Vital signs, which including heart rate (HR), respiratory rate (RR), non-invasive blood  
22  
23 pressure (BP) and pulse oxygen saturation (SpO<sub>2</sub>), are continuously monitored. VAS  
24  
25 pain score is used to measure the pain intensity by the study investigator [25]. Each  
26  
27 patient is instructed and asked to point to a mark on a 10-cm horizontal line labelled  
28  
29 with descriptors of pain intensity (‘No pain’ at the 0 cm point and ‘Extreme pain’ at the  
30  
31 10 cm point). VAS and vital signs (HR, RR, BP and SpO<sub>2</sub>) are documented at four time  
32  
33 points: before drug infusion (baseline), immediately before extubation, immediately to  
34  
35 3 minutes after extubation and 20 minutes after extubation.  
36  
37  
38  
39

40  
41 Patients will be followed up until hospital discharge, death or 60 days after the trial  
42  
43 intervention, on first-served basis. Following data are collected: incidence of  
44  
45 re-intubation within 72 hours after extubation, incidence of re-operation due to  
46  
47 intracranial hemorrhage or edema within 72 hours after extubation, LOS in ICU and  
48  
49 hospital and mortality.  
50  
51  
52

### 53 54 55 56 **Adverse events management and emergency stop of the study drug** 57 58 59 60

1  
2  
3  
4 Patients are closely monitored during study drug infusion. Taking into account the  
5  
6 potential adverse effects of remifentanyl, experimental drugs must be immediately  
7  
8 terminated when the following occurs:  
9

- 10  
11 1) Unresponsive to calling and patting on the shoulder;
- 12  
13 2) RR less than 8 respirations per minute and SpO<sub>2</sub> less than 92%;
- 14  
15 3) HR less than 50 beats per minute after atropine in 0.25 mg bolus;
- 16  
17 4) Systolic BP less than 90 mmHg;
- 18  
19 5) Serious allergic reaction such as throat swelling, bronchospasm or skin rash.
- 20  
21
- 22
- 23

24 These data will be documented and reported as adverse events.  
25  
26  
27

### 28 29 **Study endpoints**

30  
31 The primary endpoint of present study is the incidence of severe pain during  
32  
33 peri-extubation period. Peri-extubation is defined as the period of time from  
34  
35 immediately before extubation to 20 minutes after extubation. Severe pain is defined as  
36  
37 one of the VAS pain scores is more than 5 cm.  
38  
39

40  
41 Secondary endpoints include:  
42

- 43  
44 1) VAS pain score and vital signs (HR, RR, BP and SpO<sub>2</sub>) during peri-extubation  
45  
46 period;
- 47  
48 2) Incidence of failing to pass extubation evaluation after experimental drug  
49  
50 infusion;
- 51  
52 3) Incidence of re-intubation within 72 hours after extubation;
- 53  
54 4) Incidence of re-operation due to intracranial hemorrhage or edema within 72  
55  
56  
57  
58  
59  
60

hours after extubation;

- 5) Incidence of adverse events during experimental drug infusion;
- 6) LOS in ICU and hospital;
- 7) Mortality.

### **Current sample size justification**

Primarily, we expect the incidence of severe pain during peri-extubation period to decrease after remifentanyl infusion in delayed extubation patients after craniotomy.

Previous investigation showed that severe peri-extubation pain was occurred in 45% of patients [8]. It is expected that the incidence of severe pain would decrease to 30% after remifentanyl infusion. Using the Power and Sample Size Calculation program, we will need to study 74 experimental subjects and 74 control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with a probability (power) of 0.8. The Type I error probability with testing this null hypothesis is 0.05.

### **Statistical analysis**

All analyses will be according to the intention-to-treat principle, that is, all randomized patients will be analyzed in the groups to which they were originally allocated and will be blinded to treatment assignment.

Baseline characteristics will be summarized by univariate analyses. Categorical variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test.

1  
2  
3  
4 Continuous variables will be checked for normal distribution and presented as mean  
5  
6 and standard deviation or median and interquartile range as appropriate. Comparison of  
7  
8 continuous variables will be performed by using Student's t-test for normally  
9  
10 distributed variables and the Mann-Whitney U test for non-normally distributed  
11  
12 variables.  
13

14  
15  
16 We use repeated measure of analysis of variance (ANOVA) for comparing VAS pain  
17  
18 score and vital signs (HR, RR, BP and SpO<sub>2</sub>) across different time points (before drug  
19  
20 infusion and during peri-extubation period) between the two groups.  
21  
22

23  
24 All tests of significance will be at the 5% significance level, and two-sided. Analyses  
25  
26 are conducted by using SPSS 17.0.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ETHICS AND DISSEMINATION

### **Ethical aspects and informed consent**

Patients with delayed extubation after craniotomy are often unable to provide consent before extubation. After patient's eligibility for the study is confirmed, the ICU physician will introduce the family to the study coordinator. The physician will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program that is being conducted, and that this person is qualified to do so. The study coordinator will take the family to a place where they can talk confidentially. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand.

The study coordinator will explain that the patient may experience pain during extubation and, if so, the patient could become worse. The coordinator will say that a new opioid drug, remifentanil provides adequate analgesia with minimal respiratory depression. He (or she) will explain that in a small percentage of patients, remifentanil could cause bradycardia, hypotension and respiratory depression. The potential advantages of using or not using remifentanil will be described. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study

1  
2  
3 coordinator, local co-investigator and the local Ethical Committee. Written consent will  
4  
5  
6 be obtained in the presence of a witness.  
7

8  
9 A register is kept of all patients evaluated for inclusion and of patients who withdraw  
10  
11 from the study. The latter are clinically followed up without their data being analyzed in  
12  
13 the study.  
14

15  
16 The study protocol and consent forms were approved on November 1, 2013 by the  
17  
18 Institutional Review Board of Beijing Tiantan Hospital Affiliated to Capital Medical  
19  
20 University (approval number KY2013-002-01). The study was registered on November  
21  
22 8, 2013 at the Chinese Clinical Trial Registry (ChiCTR-PRC-13003879).  
23  
24  
25

### 26 27 28 **Dissemination plan** 29

30  
31 Results of the trial will be submitted to international peer reviewed journal. Results will  
32  
33 also be presented at national and international conferences relevant to subject fields.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**TRIAL STATUS**

The patient recruitment began on January 6, 2014, and the first patient was enrolled on the same day. The study will be completed in December 2014.

For peer review only

## SUMMARY

Endotracheal extubation is a critical step during post-operative care in neurosurgical patients [9]. Pain is common during extubation period, and related to complications and adverse outcome [8]. Adequate analgesia is needed in this situation. Although revised Clinical Practice Guidelines from SCCM have recommended that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to potentially painful procedures [7], study for analgesia during endotracheal extubation is still limited. As a new opioid with minimal respiratory depression effect and a rapid onset and short duration of action, remifentanyl seems suitable for prophylactic analgesia during extubation in patients after craniotomy [13-16]. We want to provide such evidence in present study. Even a neutral result will provide important insight, as this would mean that more studies are needed to explore a safe and effective way of pain management during endotracheal extubation. This is the main strength of present study. It should be emphasized the comprehensive characteristics of pain management. Apart from opioids, other analgesics (such as steroidal or non-steroidal anti-inflammatory drugs) and/or non-pharmacologic interventions (such as relaxation) have been shown to alleviate pain in adult ICU patients [7]. Although the main purpose of present study is not to clarify the effect of comprehensive approach on manipulation of pain during extubation, we will collect data of the use of analgesics during anaesthesia and ICU stay, and the formulation and dose of postoperative PCA pump. The use of non-opioids and non-pharmacologic interventions during extubation needs further investigation. Currently, vital signs are not recommended to be used alone for pain assessment [7].

1  
2  
3  
4 However, we still incorporated changes of vital signs during peri-extubation period as a  
5  
6 secondary endpoint for two reasons. First, nociceptive stimulus during endotracheal  
7  
8 extubation may result in adverse events in patients after craniotomy, such as brain  
9  
10 swelling and hemorrhage. We want to know whether remifentanil could diminish this  
11  
12 stress response. Second, because large doses of opioid agents usually result in  
13  
14 respiratory and circulatory depression, this secondary endpoint will provide safe  
15  
16 consideration about the use of these agents.  
17  
18  
19

20  
21 There are some limitations to our study protocol. First, because there is no proven dose  
22  
23 of remifentanil which can prevent sedation and respiratory depression in a  
24  
25 neurosurgical patient being weaned off ventilator, the dose of remifentanyl used in  
26  
27 present study is arbitrary. Second, we assumed a 15% reduction in severe pain after the  
28  
29 administration of remifentanil in the calculation of sample size. There are no previous  
30  
31 studies to support this. However, an effectivity of 15% is generally adopted in clinical  
32  
33 studies. Third, opioids may result in change of consciousness. We only observe the  
34  
35 response to calling and patting on the shoulder during the infusion of study agents.  
36  
37  
38  
39

40  
41 Documentation of sedation scales (such as Vancouver interaction scale or  
42  
43 sedation-agitation scale) will add value to the study. Finally, evaluation of VAS requires  
44  
45 the patient's ability to self-report clearly, and this may limit the patient population  
46  
47 eligible for the present study. So, the results of this study will not be applied to all  
48  
49 patients after craniotomy, especially for those with consciousness impairments.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions**

All authors listed on the title page fulfill the authorship criteria given by the ICMJE.

YXW and JXZ participated in the design of the study and drafted the manuscript. HC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement**

The study was funded by Beijing Health Bureau (No: 2009-3-28). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

**Competing interests**

The authors declare that they have no competing interests.

## REFERENCES

1. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. *Anesthesiology* 2007;**106**:687-95.
2. Chanques G, Sebbane M, Barbotte E, et al. A prospective study of pain at rest: Incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. *Anesthesiology* 2007;**107**:858-60.
3. Robinson BR, Mueller EW, Henson K, et al. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. *J Trauma* 2008;**65**:517-26.
4. Payen JF, Bosson JL, Chanques G, et al. DOLOREA Investigators. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: A post Hoc analysis of the DOLOREA study. *Anesthesiology* 2009;**111**:1308-16.
5. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. *Crit Care Med* 2006;**34**:1691-9.
6. Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. *Am J Crit Care* 2001;**10**:238-51.

- 1  
2  
3  
4 7. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine:  
5  
6 Clinical practice guidelines for the management of pain, agitation, and delirium  
7  
8 in adult patients in the intensive care unit. *Crit Care Med* 2013;**41**:263-306.
- 9  
10  
11 8. Gacouin A, Camus C, Le Tulzo Y, et al. Assessment of peri-extubation pain by  
12  
13 visual analogue scale in the adult intensive care unit: a prospective  
14  
15 observational study. *Intensive Care Med* 2004;**30**:1340-7.
- 16  
17  
18 9. Difficult Airway Society Extubation Guidelines Group, Popat M, Mitchell V, et  
19  
20 al. Difficult Airway Society Guidelines for the management of tracheal  
21  
22 extubation. *Anaesthesia* 2012;**67**:318-40.
- 23  
24  
25  
26 10. Cai YH, Zeng HY, Shi ZH, et al. Factors influencing delayed extubation after  
27  
28 infratentorial craniotomy for tumour resection: a prospective cohort study of  
29  
30 800 patients in a Chinese neurosurgical centre. *J Int Med Res* 2013;**41**:208-17.
- 31  
32  
33  
34 11. Cata JP, Saager L, Kurz A, et al. Successful extubation in the operating room  
35  
36 after infratentorial craniotomy: the Cleveland Clinic experience. *J Neurosurg*  
37  
38 *Anesthesiol* 2011;**23**:25-9.
- 39  
40  
41 12. Bruder N, Ravussin P. Recovery from anesthesia and postoperative extubation  
42  
43 of neurosurgical patients: a review. *J Neurosurg Anesthesiol* 1999;**11**:282-93.
- 44  
45  
46 13. Glass PS, Gan TJ, Howell S. A review of the pharmacokinetics and  
47  
48 pharmacodynamics of remifentanil. *Anesth Analg* 1999;**89(4 Suppl)**:S7-S14.
- 49  
50  
51 14. Beers R, Camporesi E. Remifentanil update: clinical science and utility. *CNS*  
52  
53 *drugs* 2004;**18**:1085-104.
- 54  
55  
56 15. Egan TD, Kern SE, Muir KT, et al. Remifentanil by bolus injection: a safety,  
57  
58  
59  
60



- 1  
2  
3  
4 pharmacokinetic, pharmacodynamic, and age effect investigation in human  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- pharmacokinetic, pharmacodynamic, and age effect investigation in human  
volunteers. *Br J Anaesth* 2004;**92**:335-43.
16. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on  
remifentanyl. *Crit Care* 2008;**12**(Suppl 3):S5.
17. Casey E, Lane A, Kuriakose D, et al. Bolus remifentanyl for chest drain removal  
in ICU: a randomized double-blind comparison of three modes of analgesia in  
post-cardiac surgical patients. *Intensive Care Med* 2010;**36**:1380-5.
18. Burlacu CL, McKeating K, McShane AJ. Remifentanyl for the insertion and  
removal of long-term central venous access during monitored anesthesia care. *J*  
*Clin Anesth* 2011;**23**:286-91.
19. Le Floch R, Naux E, Pilorget A, et al. Use of remifentanyl for analgesia during  
dressing change in spontaneously breathing non-intubated burn patients. *Ann*  
*Burns Fire Disasters* 2006;**19**:136-9.
20. Leone M, Albanese J, Viviani X, et al. The effects of remifentanyl on  
endotracheal suctioning-induced increases in intracranial pressure in  
head-injured patients. *Anesth Analg* 2004;**99**:1193-8.
21. Kim SY, Yang SY, Na SW, et al. Low-dose remifentanyl infusion during  
ventilator weaning and tracheal extubation in postoperative intensive care unit  
patients sedated with propofol-remifentanyl: a randomised clinical trial. *Anaesth*  
*Intensive Care* 2012;**40**:656-62.
22. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanyl on intracranial  
pressure and cerebral blood flow velocity in patients with head trauma. *Acta*

1  
2  
3  
4 Anaesthesiol Scand 2004;**48**:396-9.  
5

- 6 23. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of  
7  
8 analgesia- based sedation using remifentanyl versus standard hypnotic-based  
9  
10 regimens in intensive care unit patients with brain injuries: a randomised,  
11  
12 controlled trial [ISRCTN50308308]. Crit Care 2004;**8**:R268-R280.  
13  
14  
15  
16  
17 24. Bauer C, Kreuer S, Ketter R, et al. Remifentanyl-propofol versus  
18  
19 fentanyl-midazolam combina- tions for intracranial surgery: Influence of  
20  
21 anaesthesia tech- nique and intensive sedation on ventilation times and duration  
22  
23 of stay in the ICU. Anaesthesist 2007;**56**:128-32.  
24  
25  
26  
27  
28 25. Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg  
29  
30 Med 1996;**27**:427-32.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1: Screening checklist used to determine the patient's suitability for extubation**

Question	Answer
1. Awake and alert with cerebral function adequate for patient co-operation or equivalent preoperative state of consciousness?	Yes/No
2. Hemodynamic stability (lack of vasopressor support and mean arterial pressure within 10-15% of baseline)?	Yes/No
3. Adequate recovery of muscle strength?	Yes/No
4. Normal tidal volumes, normocapnia (end-tidal carbon dioxide 30-45 mmHg), minimum pulse oximetry > 95% with FiO <sub>2</sub> 0.5?	Yes/No
5. Intact gag reflex and swallow function (presence of clearly audible cough during suctioning)?	Yes/No

The answer to all questions must be "yes" in order for extubation to be approved.

FiO<sub>2</sub>: fraction of inspired oxygen

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Figure legend

Figure 1: Trial schematic diagram

For peer review only

1  
2  
3  
4  
5  
6  
7 **Short-term use of remifentanil during endotracheal extubation for prophylactic**  
8 **analgesia in neurosurgical patients after craniotomy (SURE after Craniotomy**  
9 **Study): a study protocol and statistical analysis plan for a randomized controlled**  
10 **trial**  
11  
12  
13  
14

15  
16  
17  
18 Yuan-Xing Wu, Han Chen, Jian-Xin Zhou\*

19  
20 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical  
21 University, Beijing, 100050, China  
22  
23

24  
25  
26  
27 \*: Corresponding author

28  
29 Jian-Xin Zhou

30  
31 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical  
32 University  
33

34  
35 Address: No 6, Tiantan Xili, Dongcheng district, Beijing, 100050, China

36  
37 Telephone: +8610 67098019

38  
39 Email: zhoujx.cn@gmail.com  
40  
41

42  
43  
44 Keywords: remifentanil, analgesia, prophylactic, extubation, craniotomy  
45  
46

47  
48  
49 Word count: 44092569  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Introduction:** Acute pain is common during endotracheal extubation period, and is related to complications and adverse outcomes. Patients with delayed extubation after craniotomy are vulnerable to pain and complications of extubation. However, pain control during extubation is still inadequate. Remifentanyl, a new opioid with rapid onset and short duration of action, provides adequate analgesia during procedures with minimal effect of respiratory depression.

**Methods and analysis:** The study is a prospective, randomized, double-blinded, controlled, parallel-group design. Patients with delayed extubation after intracranial surgery are screened daily. Adult patients ready for extubation are enrolled and assigned randomly to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Patients in Remi group receive intravenous bolus dose of remifentanyl 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride at a volume and rate equal to that of remifentanyl. Pain intensity is measured by visual analog scale (VAS) pain score. Adverse events during drug infusion are documented and reported. Patients will be followed up until hospital discharge, death or 60 days after the trial intervention, on first-served basis. Incidence of re-intubation and re-operation within 72 hours after extubation, length of stay in intensive care unit and hospital and mortality are collected. The primary endpoint is the incidence of severe pain (defined as VAS pain score more than 5 cm) during peri-extubation period (defined as the period of time from immediately before extubation to 20 minutes after

1  
2  
3  
4  
5  
6  
7 extubation).

8  
9 **Ethics and dissemination:** The study was approved by the IRB of Beijing Tiantan  
10 Hospital, Capital Medical University. Study findings will be disseminated through  
11 peer-reviewed publications and conference presentations.  
12  
13

14  
15 **Trial Registration:** ClinicalTrials (NCT): ChiCTR-PRC-13003879.  
16  
17

### 18 19 20 **Main strengths and limitations of the study**

21  
22 Pain is common during extubation period, and related to complications and adverse  
23 outcome. Adequate analgesia is needed in this situation. The main strength of the study  
24 is that we will provide the evidence of a new opioid (remifentanil) with minimal  
25 respiratory depression effect and a rapid onset and short duration of action, for  
26 prophylactic analgesia during extubation in patients after craniotomy.  
27  
28

29  
30  
31  
32  
33 Pain management is a comprehensive algorithm, which includes pharmacologic and  
34 non-pharmacologic interventions. In present study, only remifentanil is investigated  
35 ~~Other opioids may be suitable~~ for prophylactic analgesia during extubation. This is the  
36 ~~The main limitation of the study is that we do not use other opioids, such as morphine~~  
37 ~~or fentanyl, as control groups.~~ Because there is no proven dose of remifentanil which  
38 can prevent sedation and respiratory depression in a neurosurgical patient being  
39 weaned off ventilator, the dose of ~~remifentanil~~remifentanil used in present study is  
40 arbitrary. The evaluation of visual analog scale requires the patient's ability to  
41 self-report clearly, and this may limit the patient population eligible for the present  
42 study. So, the results of this study will not be applied to all patients after craniotomy.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

especially for those with consciousness impairments.

**Formatted:** Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

For peer review only

## INTRODUCTION

Clinical epidemiology studies have shown that critically ill patients in intensive care unit (ICU) are at high-risk of pain, and inadequate treatment of pain is associated with adverse outcomes [1,2]. Appropriate analgesia, not only attenuates stress response resulted from pain, but also reduces the incidence of iatrogenic complications, shorten the duration of mechanical ventilation and length of stay (LOS) in ICU [3-5]. In addition to pain at rest, pain related to procedures is common in ICU patients, and inadequate treatment of procedural pain remains a significant problem for many patients [6]. The revised clinical practice guidelines for management of pain, agitation, and delirium from Society of Critical Care Medicine (SCCM) also recommend that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to chest tube removal and other types of potentially painful procedures, and suggest that intravenous opioids should be considered as the first-line drug class of choice [7]. Manipulation of artificial airway, especially endotracheal extubation is among the high pain-intensity procedures in ICU. By using the patient's self-report pain scale as pain evaluation method, Gacouin et al. found that 45% of patients experienced severe pain at the time of endotracheal extubation [8]. Acute pain during extubation is associated with sympathetic nervous system activation, which could result in respiratory and circulatory instability [9]. Therefore, it is reasonable to control pain and stress responses at the time of endotracheal extubation in some high-risk patients, such as those after intracranial surgery. It has been reported that the proportion of patients who underwent delayed extubation after craniotomy is about 10% to 50% [10,11]. These

1  
2  
3  
4  
5  
6  
7 patients are vulnerable to pain and complications of extubation [12]. On the other hand,  
8  
9 despite a greater awareness of pain during endotracheal extubation, clinicians remain  
10  
11 reluctant to administer opioids in patients following craniotomy. The major concern is  
12  
13 the side effects of respiratory depression and influence on consciousness of these drugs.  
14  
15 To our knowledge, up to now, no study has been published for adequate management of  
16  
17 pain during extubation in patients with delayed extubation after craniotomy.

18  
19 Remifentanyl is a potent synthetic selective  $\mu$ -opioid receptor agonist with a rapid onset  
20  
21 and short duration of action, regardless of the duration of its administration [13,14].  
22  
23

24  
25 Remifentanyl differs from other synthetic opioids in its metabolism by non-specific  
26  
27 plasma and tissue esterases. Study in human volunteers has shown that the respiratory  
28  
29 depression of remifentanyl by bolus injection is mild and easily treated with requests to  
30  
31 breathe or the administration of oxygen [15]. These pharmacological properties suggest  
32  
33 that remifentanyl could be a potentially safe and effective analgesic in clinical situations  
34  
35 requiring a brief period of intense control of pain, such as painful procedures in ICU  
36  
37 [16]. There have been reported remifentanyl used as prophylactic analgesia during  
38  
39 removal of chest drain [17], insertion and removal of long-term central venous access  
40  
41 [18], dressing change [19], and endotracheal suctioning [20]. However, although a  
42  
43 plenty of studies have shown that the remifentanyl facilitates emergency in general  
44  
45 anesthesia and weaning process in mechanical ventilation [14,16,21], study for  
46  
47 prophylactic use of remifentanyl in endotracheal extubation is limited.  
48  
49

50  
51 There has been increased interest in use of remifentanyl in brain injured patients. In  
52  
53 patients with traumatic brain injury, it has been demonstrated that remifentanyl has no  
54  
55

1  
2  
3  
4  
5  
6  
7 significant changes in systematic and cerebral hemodynamics, such as intracranial  
8  
9 pressure, mean blood pressure, cerebral perfusion pressure, and cerebral blood flow  
10  
11 velocity [22]. Several studies also compared remifentanyl with fentanyl or morphine as  
12  
13 analgesic in neurologic ICU patients. A randomized multicenter study in patients with  
14  
15 brain injury showed that mean neurologic assessment times were significantly shorter  
16  
17 with remifentanyl than with fentanyl or with morphine, and patients were extubated  
18  
19 significantly faster after remifentanyl than after morphine [23]. Another retrospective  
20  
21 study investigated patients with delayed extubation after brain tumor surgery, and  
22  
23 found that mean extubation times were significantly shorter after remifentanyl/propofol  
24  
25 than after fentanyl/midazolam, and LOS in ICU was significantly reduced [24]. These  
26  
27 results indicate that the rapid metabolism and lack of accumulation of remifentanyl  
28  
29 facilitate faster waking and neurological assessment, and suggest that remifentanyl  
30  
31 might be a better choice of analgesic in patients with brain injury.  
32  
33

34  
35 In present study, remifentanyl is used as prophylactic analgesics in patients with delayed  
36  
37 extubation after craniotomy. The aim is to evaluate the efficacy and safety of  
38  
39 remifentanyl for control of pain and stress responses due to extubation. The primary  
40  
41 hypothesis is that prophylactic use of remifentanyl will reduce the incidence of severe  
42  
43 pain during endotracheal extubation.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

### Study design overview

The present study is a prospective, single-center, randomized, double-blinded, placebo-controlled, two-arm trial in patients with delayed extubation after craniotomy. Trial schematic diagram is shown in Figure 1.

### Study setting and population

The study setting is neurosurgical ICU (30 beds), Beijing Tiantan Hospital (1100 beds), Capital Medical University, Beijing, China.

All patients after intracranial surgery with delayed extubation admitted to our ICU are screened daily for study eligibility.

Inclusion criteria are:

- 1) Age between 18-65 years-old;
- 2) Within 72 hours after operation;
- 3) Awaken and able to cope with the assessment of visual analog scale (VAS) pain score;
- 4) Ready for extubation after evaluated by neurosurgeon and ICU physician in charge.

Exclusion criteria are:

- 1) Operation relating to medulla oblongata region;
- 2) Hepatic Insufficiency;

- 3) Renal insufficiency;
- 4) Pregnant or lactating women;
- 5) Need continuous infusion of vasopressor before the start of study drug infusion;
- 6) Chronic opioid use over three months;
- 7) Known opioids allergy;
- 8) Readmitted to ICU after randomization to the study;
- 9) Enrolled in another trial.

Patient's endotracheal tube is extubated at the discretion of neurosurgeon and ICU physician in charge of the patient. Neurosurgeon and ICU physician discuss the patient's status and evaluate the patient by a screen checklist (Table 1) [10]. When answers of all items in checklist are "yes", the patient is ready for extubation. At this time, a 24-hour on-call study coordinator will be informed immediately, and patient's eligibility for the study is evaluated and confirmed.

#### **Randomization, double-blind and allocation concealment**

The study has a prospective, randomized, double-blinded, controlled, parallel-group design. Randomization is based on computer generated random digits table. The allocation sequence is sealed in numbered and opaque envelopes to ensure that the sequence is concealed. Consecutive Enrolled patients are randomly assigned 1:1 to receive remifentanyl (labeled as Remi group) or placebo (labeled as Saline group) infusion to one of the two treatment study groups, labeled as 'Remi group' or 'Saline group'. Randomization is based on computer generated random digits table and follows

1  
2  
3  
4  
5  
6  
7 ~~a concealed process using sealed and numbered envelopes that allocate the patient to~~  
8 ~~either of the two arms of the study.~~ Patients may be randomized into this study only  
9  
10  
11 once unless they were discharged from the hospital and were re-admitted beyond 180  
12  
13 days of the first enrollment. The study does not allow cross-over and, if any occur, they  
14  
15 will be reported as protocol violations.  
16

17  
18 Experimental drug and placebo with the same character are prepared by a pharmacist.  
19  
20 Patients and all study personnel except the investigative pharmacist are blind to  
21  
22 treatment assignment. The details of the series are unknown to any of the investigators  
23  
24 and are contained in a set of opaque and sealed envelopes, each bearing on the outside  
25  
26 only the number.  
27  
28  
29  
30

### 31 **Data collected at study entry**

32  
33 At baseline, data on demographic, history of past illness characteristics and diagnosis  
34  
35 of the patients are obtained. The surgical site, operation time, use of sedatives and  
36  
37 analgesics during anaesthesia and ICU stay, time of mechanical ventilation,  
38  
39 formulation and dose of postoperative patient-control-analgesia (PCA) pump, and time  
40  
41 between end of operation and study drug infusion are recorded. Acute Physiology and  
42  
43 Chronic Health Evaluation II score (APACHE II) is calculated.  
44  
45  
46  
47  
48

### 49 **Trial interventions**

50  
51 All patients are randomized 1:1 to receive remifentanyl (Remi group) or placebo (Saline  
52  
53 group) infusion. Patients in Remi group receive intravenous bolus dose of remifentanyl  
54  
55

1  
2  
3  
4  
5  
6  
7 0.5 µg/kg over 60 seconds followed by a continuous infusion 0.05µg/kg/min for 20  
8  
9 minutes. Patients in Saline group receive intravenous infusion of 0.9% sodium chloride  
10  
11 at a volume and rate equal to that of remifentanyl. Study drugs are administered by  
12  
13 using syringe pump.

14  
15 Immediately after drug infusion, ICU physician evaluate the patient by using  
16  
17 extubation screen checklist shown in Table 1. If the patient passes the evaluation,  
18  
19 endotracheal extubation will be carried out immediately by registered ICU nurses. The  
20  
21 patient will be labeled as “failing to pass extubation test after drug administration” if he  
22  
23 or she does not pass the evaluation. The reason of test failure will be documented. The  
24  
25 patient will be re-evaluated every hour thereafter, and data about extubation will be  
26  
27 documented.

28  
29  
30  
31 Vital signs, which including heart rate (HR), respiratory rate (RR), non-invasive blood  
32  
33 pressure (BP) and pulse oxygen saturation (SpO<sub>2</sub>), are continuously monitored. VAS  
34  
35 pain score is used to measure the pain intensity by the study investigator [25]. Each  
36  
37 patient is instructed and asked to point to a mark on a 10-cm horizontal line labelled  
38  
39 with descriptors of pain intensity (‘No pain’ at the 0 cm point and ‘Extreme pain’ at the  
40  
41 10 cm point). VAS and vital signs (HR, RR, BP and SpO<sub>2</sub>) are documented at four time  
42  
43 points: before drug infusion (baseline), immediately before extubation, immediately to  
44  
45 3 minutes after extubation and 20 minutes after extubation.

46  
47  
48  
49 Patients will be followed up until hospital discharge, death or 60 days after the trial  
50  
51 intervention, on first-served basis. Following data are collected: incidence of  
52  
53 re-intubation within 72 hours after extubation, incidence of re-operation due to  
54  
55



1  
2  
3  
4  
5  
6 intracranial hemorrhage or edema within 72 hours after extubation, LOS in ICU and  
7  
8 hospital and mortality.  
9

### 10 11 12 13 **Adverse events management and emergency stop of the study drug**

14  
15 Patients are closely monitored during study drug infusion. Taking into account the  
16  
17 potential adverse effects of remifentanyl, experimental drugs must be immediately  
18  
19 terminated when the following occurs:  
20

- 21 1) Unresponsive to calling and patting on the shoulder;
- 22 2) RR less than 8 respirations per minute and SpO<sub>2</sub> less than 92%;
- 23 3) HR less than 50 beats per minute after atropine in 0.25 mg bolus;
- 24 4) Systolic BP less than 90 mmHg;
- 25 5) Serious allergic reaction such as throat swelling, bronchospasm or skin rash.

26  
27  
28  
29 These data will be documented and reported as adverse events.  
30  
31  
32

### 33 34 35 36 37 **Study endpoints**

38  
39 The primary endpoint of present study is the incidence of severe pain during  
40  
41 peri-extubation period. Peri-extubation is defined as the period of time from  
42  
43 immediately before extubation to 20 minutes after extubation. Severe pain is defined as  
44  
45 one of the VAS pain scores is more than 5 cm.  
46  
47

48  
49 Secondary endpoints include:

- 50 1) VAS pain score and vital signs (HR, RR, BP and SpO<sub>2</sub>) during peri-extubation  
51  
52 period;  
53  
54  
55  
56

- 2) Incidence of failing to pass extubation evaluation after experimental drug infusion;
- 3) Incidence of re-intubation within 72 hours after extubation;
- 4) Incidence of re-operation due to intracranial hemorrhage or edema within 72 hours after extubation;
- 5) Incidence of adverse events during experimental drug infusion;
- 6) LOS in ICU and hospital;
- 7) Mortality.

#### **Current sample size justification**

Primarily, we expect the incidence of severe pain during peri-extubation period to decrease after remifentanyl infusion in delayed extubation patients after craniotomy.

Previous investigation showed that severe peri-extubation pain was occurred in 45% of patients [8]. It is expected that the incidence of severe pain would decrease to 30% after remifentanyl infusion. Using the Power and Sample Size Calculation program, we will need to study 74 experimental subjects and 74 control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with a probability (power) of 0.8. The Type I error probability with testing this null hypothesis is 0.05.

#### **Statistical analysis**

All analyses will be according to the intention-to-treat principle, that is, all randomized

1  
2  
3  
4  
5  
6 patients will be analyzed in the groups to which they were originally allocated and will  
7  
8 be blinded to treatment assignment.  
9

10  
11 Baseline characteristics will be summarized by univariate analyses. Categorical  
12  
13 variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test.  
14

15  
16 Continuous variables will be checked for normal distribution and presented as mean  
17  
18 and standard deviation or median and interquartile range as appropriate. Comparison of  
19  
20 continuous variables will be performed by using Student's t-test for normally  
21  
22 distributed variables and the Mann-Whitney U test for non-normally distributed  
23  
24 variables.  
25

26  
27 We use repeated measure of analysis of variance (ANOVA) for comparing VAS pain  
28  
29 score and vital signs (HR, RR, BP and SpO<sub>2</sub>) across different time points (before drug  
30  
31 infusion and during peri-extubation period) between the two groups.  
32

33  
34 All tests of significance will be at the 5% significance level, and two-sided. Analyses  
35  
36 are conducted by using SPSS 17.0.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ETHICS AND DISSEMINATION

### Ethical aspects and informed consent

Patients with delayed extubation after craniotomy are often unable to provide consent before extubation. After patient's eligibility for the study is confirmed, the ICU physician will introduce the family to the study coordinator. The physician will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program that is being conducted, and that this person is qualified to do so. The study coordinator will take the family to a place where they can talk confidentially. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand.

The study coordinator will explain that the patient may experience pain during extubation and, if so, the patient could become worse. The coordinator will say that a new opioid drug, remifentanil provides adequate analgesia with minimal respiratory depression. He (or she) will explain that in a small percentage of patients, remifentanil could cause bradycardia, hypotension and respiratory depression. The potential advantages of using or not using remifentanil will be described. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study

1  
2  
3  
4  
5  
6  
7 coordinator, local co-investigator and the local Ethical Committee. Written consent will  
8  
9 be obtained in the presence of a witness.

10  
11 A register is kept of all patients evaluated for inclusion and of patients who withdraw  
12  
13 from the study. The latter are clinically followed up without their data being analyzed in  
14  
15 the study.

16  
17  
18 The study protocol and consent forms were approved on November 1, 2013 by the  
19  
20 Institutional Review Board of Beijing Tiantan Hospital Affiliated to Capital Medical  
21  
22 University (approval number KY2013-002-01). The study was registered on November  
23  
24 8, 2013 at the Chinese Clinical Trial Registry (ChiCTR-PRC-13003879).

### 25 26 27 28 29 **Dissemination plan**

30  
31 Results of the trial will be submitted to international peer reviewed journal. Results will  
32  
33 also be presented at national and international conferences relevant to subject fields.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**TRIAL STATUS**

The patient recruitment began on January 6, 2014, and the first patient was enrolled on the same day. The study will be completed in December 2014.

For peer review only

## SUMMARY

Endotracheal extubation is a critical step during post-operative care in neurosurgical patients [9]. Pain is common during extubation period, and related to complications and adverse outcome [8]. Adequate analgesia is needed in this situation. Although revised Clinical Practice Guidelines from SCCM have recommended that prophylactic analgesia should be used to alleviate pain in adult ICU patients prior to potentially painful procedures [7], study for analgesia during endotracheal extubation is still limited. As a new opioid with minimal respiratory depression effect and a rapid onset and short duration of action, remifentanyl seems suitable for prophylactic analgesia during extubation in patients after craniotomy [13-16]. We want to provide such evidence in present study. Even a neutral result will provide important insight, as this would mean that more studies are needed to explore a safe and effective way of pain management during endotracheal extubation. This is the main strength of present study.

It should be emphasized the comprehensive characteristics of pain management. Apart from opioids, other analgesics (such as steroidal or non-steroidal anti-inflammatory drugs) and/or non-pharmacologic interventions (such as relaxation) have been shown to alleviate pain in adult ICU patients [7]. Although the main purpose of present study is not to clarify the effect of comprehensive approach on manipulation of pain during extubation, we will collect data of the use of analgesics during anaesthesia and ICU stay, and the formulation and dose of postoperative PCA pump. The use of non-opioids and non-pharmacologic interventions during extubation needs further investigation. Currently, vital signs are not recommended to be used alone for pain assessment [7].

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

1  
2  
3  
4  
5  
6  
7 However, we still incorporated changes of vital signs during peri-extubation period as a  
8 secondary endpoint for two reasons. First, nociceptive stimulus during endotracheal  
9 extubation may result in adverse events in patients after craniotomy, such as brain  
10 swelling and hemorrhage. We want to know whether remifentanyl could diminish this  
11 stress response. Second, because large doses of opioid agents usually result in  
12 respiratory and circulatory depression, this secondary endpoint will provide safe  
13 consideration about the use of these agents.

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There are some limitations to our study protocol. First, because there is no proven dose of remifentanyl which can prevent sedation and respiratory depression in a neurosurgical patient being weaned off ventilator, the dose of remifentanyl used in present study is arbitrary. Second, we assumed a 15% reduction in severe pain after the administration of remifentanyl in the calculation of sample size. There are no previous studies to support this. However, an effectivity of 15% is generally adopted in clinical studies. Third, opioids may result in change of consciousness. We only observe the

Formatted: Font: Times New Roman

response to calling and patting on the shoulder during the infusion of study agents.  
Documentation of sedation scales (such as Vancouver interaction scale or  
sedation-agitation scale) will add value to the study. Finally, evaluation of VAS requires  
the patient's ability to self-report clearly, and this may limit the patient population  
eligible for the present study. So, the results of this study will not be applied to all  
patients after craniotomy, especially for those with consciousness impairments.

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt



## REFERENCES

1. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. *Anesthesiology* 2007;**106**:687-95.
2. Chanques G, Sebbane M, Barbotte E, et al. A prospective study of pain at rest: Incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. *Anesthesiology* 2007;**107**:858-60.
3. Robinson BR, Mueller EW, Henson K, et al. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. *J Trauma* 2008;**65**:517-26.
4. Payen JF, Bosson JL, Chanques G, et al. DOLOREA Investigators. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: A post Hoc analysis of the DOLOREA study. *Anesthesiology* 2009;**111**:1308-16.
5. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. *Crit Care Med* 2006;**34**:1691-9.
6. Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. *Am J Crit Care* 2001;**10**:238-51.
7. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine:

- 1  
2  
3  
4  
5  
6  
7 Clinical practice guidelines for the management of pain, agitation, and delirium  
8  
9 in adult patients in the intensive care unit. *Crit Care Med* 2013;**41**:263-306.
- 10  
11 8. Gacouin A, Camus C, Le Tulzo Y, et al. Assessment of peri-extubation pain by  
12  
13 visual analogue scale in the adult intensive care unit: a prospective  
14  
15 observational study. *Intensive Care Med* 2004;**30**:1340-7.
- 16  
17  
18 9. Difficult Airway Society Extubation Guidelines Group, Popat M, Mitchell V, et  
19  
20 al. Difficult Airway Society Guidelines for the management of tracheal  
21  
22 extubation. *Anaesthesia* 2012;**67**:318-40.
- 23  
24  
25 10. Cai YH, Zeng HY, Shi ZH, et al. Factors influencing delayed extubation after  
26  
27 infratentorial craniotomy for tumour resection: a prospective cohort study of  
28  
29 800 patients in a Chinese neurosurgical centre. *J Int Med Res* 2013;**41**:208-17.
- 30  
31  
32 11. Cata JP, Saager L, Kurz A, et al. Successful extubation in the operating room  
33  
34 after infratentorial craniotomy: the Cleveland Clinic experience. *J Neurosurg*  
35  
36 *Anesthesiol* 2011;**23**:25-9.
- 37  
38  
39 12. Bruder N, Ravussin P. Recovery from anesthesia and postoperative extubation  
40  
41 of neurosurgical patients: a review. *J Neurosurg Anesthesiol* 1999;**11**:282-93.
- 42  
43  
44 13. Glass PS, Gan TJ, Howell S. A review of the pharmacokinetics and  
45  
46 pharmacodynamics of remifentanyl. *Anesth Analg* 1999;**89**(4 Suppl):S7-S14.
- 47  
48  
49 14. Beers R, Camporesi E. Remifentanyl update: clinical science and utility. *CNS*  
50  
51 *drugs* 2004;**18**:1085-104.
- 52  
53  
54 15. Egan TD, Kern SE, Muir KT, et al. Remifentanyl by bolus injection: a safety,  
55  
56 pharmacokinetic, pharmacodynamic, and age effect investigation in human  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7 volunteers. *Br J Anaesth* 2004;**92**:335-43.
- 8  
9 16. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on  
10 remifentanyl. *Crit Care* 2008;**12**(Suppl 3):S5.
- 11  
12  
13 17. Casey E, Lane A, Kuriakose D, et al. Bolus remifentanyl for chest drain removal  
14 in ICU: a randomized double-blind comparison of three modes of analgesia in  
15 post-cardiac surgical patients. *Intensive Care Med* 2010;**36**:1380-5.
- 16  
17  
18 18. Burlacu CL, McKeating K, McShane AJ. Remifentanyl for the insertion and  
19 removal of long-term central venous access during monitored anesthesia care. *J*  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
19. Le Floch R, Naux E, Pilorget A, et al. Use of remifentanyl for analgesia during  
dressing change in spontaneously breathing non-intubated burn patients. *Ann*  
*Burns Fire Disasters* 2006;**19**:136-9.
20. Leone M, Albanese J, Viviani X, et al. The effects of remifentanyl on  
endotracheal suctioning-induced increases in intracranial pressure in  
head-injured patients. *Anesth Analg* 2004;**99**:1193-8.
21. Kim SY, Yang SY, Na SW, et al. Low-dose remifentanyl infusion during  
ventilator weaning and tracheal extubation in postoperative intensive care unit  
patients sedated with propofol-remifentanyl: a randomised clinical trial. *Anaesth*  
*Intensive Care* 2012;**40**:656-62.
22. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanyl on intracranial  
pressure and cerebral blood flow velocity in patients with head trauma. *Acta*  
*Anaesthesiol Scand* 2004;**48**:396-9.

- 1  
2  
3  
4  
5  
6  
7 23. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of  
8 analgesia- based sedation using remifentanil versus standard hypnotic-based  
9 regimens in intensive care unit patients with brain injuries: a randomised,  
10 controlled trial [ISRCTN50308308]. Crit Care 2004;**8**:R268-R280.  
11  
12  
13  
14  
15  
16 24. Bauer C, Kreuer S, Ketter R, et al. Remifentanil-propofol versus  
17 fentanyl-midazolam combina- tions for intracranial surgery: Influence of  
18 anaesthesia tech- nique and intensive sedation on ventilation times and duration  
19 of stay in the ICU. Anaesthetist 2007;**56**:128-32.  
20  
21  
22  
23  
24  
25  
26 25. Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg  
27 Med 1996;**27**:427-32.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Authors' contributions

All authors listed on the title page fulfill the authorship criteria given by the ICMJE.

Formatted: Font: Times New Roman

Formatted: Font: Times New Roman

YXW and JXZ participated in the design of the study and drafted the manuscript. HC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

### Funding statement

The study was funded by Beijing Health Bureau (No: 2009-3-28). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

### Competing interests

The authors declare that they have no competing interests.

**Table 1: Screening checklist used to determine the patient's suitability for****extubation**

Question	Answer
1. Awake and alert with cerebral function adequate for patient co-operation or equivalent preoperative state of consciousness?	Yes/No
2. Hemodynamic stability (lack of vasopressor support and mean arterial pressure within 10-15% of baseline)?	Yes/No
3. Adequate recovery of muscle strength?	Yes/No
4. Normal tidal volumes, normocapnia (end-tidal carbon dioxide 30-45 mmHg), minimum pulse oximetry > 95% with FiO <sub>2</sub> 0.5?	Yes/No
5. Intact gag reflex and swallow function (presence of clearly audible cough during suctioning)?	Yes/No

The answer to all questions must be "yes" in order for extubation to be approved.


FiO<sub>2</sub>: fraction of inspired oxygen

1  
2  
3  
4  
5  
6  
7 **Figure legend**  
8

9  
10 Figure 1: Trial schematic diagram  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



111x90mm (300 x 300 DPI)

View Only





## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4-6
	2b	Specific objectives or hypotheses	6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7, 9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Not applicable
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	9-11
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	11-12
	6b	Any changes to trial outcomes after the trial commenced, with reasons	Not applicable
Sample size	7a	How sample size was determined	12
	7b	When applicable, explanation of any interim analyses and stopping guidelines	Not applicable
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	8-9
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8-9
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8-9
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8-9
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8-9

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	8-9
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	12-13
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	Not applicable
7			
8	<b>Results</b>		
9	Participant flow (a diagram is strongly recommended)	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Not applicable in items 13a to 22
10			
11			
12		13b For each group, losses and exclusions after randomisation, together with reasons	
13	Recruitment	14a Dates defining the periods of recruitment and follow-up	
14		14b Why the trial ended or was stopped	
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
17			
18	Outcomes and estimation	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
19		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
20	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
21			
22	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
23			
24	<b>Discussion</b>		
25	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
26	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	
27	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
28			
29	<b>Other information</b>		
30	Registration	23 Registration number and name of trial registry	ChiCTR-PRC-13003879
31			
32	Protocol	24 Where the full trial protocol can be accessed, if available	Not applicable
33	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	The study was supported by Beijing Health
34			
35			
36			
37			
38			
39			
40			
41			
42			

---

Bureau (No: 2009-3-28).  
The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

---

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).